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ABSTRACT 
Social phobia (SP) is a highly prevalent and chronic condition associated with a number of 
negative outcomes, including significant impairments in social, occupational, and educational 
functioning (Stein & Kean, 2000). Fortunately, there is substantial evidence to support the efficacy of 
cognitive behavioral and pharmacological interventions for SP immediately following treatment 
(McCabe & Antony, 2008). Less is known, however, about the extent to which treatment gains are 
maintained over the long-term. The current study examined long-term outcomes of two cognitive 
behavioral treatments for SP, Exposure Group Therapy (EGT) and Virtual Reality Exposure Therapy (VRE). 
Guided by theories of state dependent and extinction learning, we also sought to explore the extent to 
which concurrent use of psychotropic medication during treatment attenuated long-term responses to 
exposure therapy. Eligible participants (N = 75) were individuals had who previously completed either 
EGT or VRE as a part of two larger treatment studies. Thirty-four participants completed the long-term 
follow-up assessment which occurred several years (M = 5.7) after the completion of treatment and 
consisted of self-report measures, a structured clinical interview, and a behavioral avoidance test. We 
hypothesized that treatment completers would (1) exhibit fewer SP symptoms at long-term follow-up, 
relative to pre-treatment and would (2) maintain post-treatment gains over the long-term follow-up 
period. Lastly, we predicted that (3) concurrent medication use, during treatment, would be associated 
with diminished treatment gains at long term-follow-up for individuals who had discontinued 
medication during the follow-up period. Results revealed a significant effect of time on self-report and 
behavioral ratings of SP with clinically significant improvement observed from pre-treatment to long-
term follow-up (p < .05). No significant difference differences were observed from post-treatment to 
long-term follow-up (p >.05) which suggests that that post-treatment gains were well maintained in the 
long-term. We were unable to test our hypothesis that psychotropic medication would attenuate long-
term treatment gains due to the fact that only one participant had taken medication during treatment 
that was discontinued during follow-up. In sum, the current study suggests that EGT and VRE post-
treatment gains are maintained in the long run up to seven years after the completion of treatment. 
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1 INTRODUCTION  
1.1 Background 
Social phobia is characterized by an intense fear of embarrassment and of being negatively 
evaluated in social and performance situations (American Psychological Association, 2000). Socially 
phobic individuals commonly exhibit hypersensitivity to criticism or scrutiny from others and tend to 
have a poor perception of themselves as social beings. Individuals diagnosed with generalized social 
phobia exhibit intense and pervasive fears that generalize across a variety of social settings, such as 
speaking in public, going to a party, or eating in front of others (APA, 2000).  Lifetime prevalence rates 
for social phobia range from 10-13% in the general population, making it the third most prevalent 
psychological disorder and the most common anxiety disorder in the United States (Kessler, et al., 2005). 
Fear of public speaking is the most commonly reported symptom of social phobia in clinical samples 
(Furmark, Tillfors, Stattin, Ekselius, & Fredrickson, 2000). Indeed, public speaking fears alone have been 
associated with lower income, decreased likelihood of achieving post-secondary education, and 
increased likelihood of unemployment (Stein, Walker, & Forde, 1994).  
Retrospective findings have highlighted the chronic nature of social phobia, with as many as 50 
to 80% of affected individuals reporting that their struggles began in childhood (Otto et al., 2001; 
Stemberger et al., 1995). Early onset of social phobia is associated with a more chronic and severe 
course (Beidel & Turner, 2007). Research has further highlighted the chronic nature of social phobia; 
retrospective data have suggested that the mean duration of SP is approximately twenty-five years 
(DeWitt et al., 1999; Kessler et al., 1998). Despite its chronic nature and the negative effects that are 
associated with social phobia, treatment utilization in this population is particularly low in comparison to 
other anxiety disorders (Magee et al., 1996). Unfortunately, untreated social phobia is characterized by 
a chronic and unremitting course (Beidel & Turner, 2007), and longitudinal studies suggest that 
untreated social phobia can last for years and even decades (Chartier et al., 1998; Keller, 2003). 
2 
1.1.1 Models of Social Phobia 
Two models of social phobia have been particularly influential in guiding research and treatment 
for this disorder. Clark and Wells’ cognitive model (e.g., Clark and Wells, 1995; Clark, 2001) suggests that 
social phobia develops in response to faulty cognitions. Specifically, individuals with social phobia 
believe that, (1) “they are in danger of behaving in an inept fashion, and that (2) “such behavior will 
have disastrous consequences in terms of loss of status, loss of worth, and rejection” (pp. 69-70). Safety 
behaviors and post-event processing are thought to contribute to the maintenance of faulty cognitions 
that underlie social phobia. Safety behaviors are actions that are taken to prevent the occurrence of 
feared social outcomes (e.g., avoiding eye contact so others can’t see how scared a person is, excessive 
preparation to prevent looking “stupid”). Following social interactions, individuals with social phobia 
tend to engage in post-event processing (PEP), which is characterized by a detailed review of the social 
event or interaction. Unfortunately, negative elements of the social event, including perceived 
inadequacies, mistakes, and imperfections tend to dominate PEP for individuals with social phobia 
(Rachman, Grater-Andrew, & Shafran, 2000). PEP is thought to perpetuate intrusive maladaptive 
cognitions about social interactions and to lower anticipation of success in future social situations 
(Abbott & Rapee, 2004; Rachman, Grater-Andrew et al., 2000). Research with clinical samples has 
consistently supported the relation between PEP and social anxiety (Abbott & Rapee, 2004; Coles, Turk, 
& Heimberg, 2002; Kocovski & Rector, 2008; Perini, Abbott & Rapee, 2006). 
Rapee & Heimberg’s (1997) model is based on the notion that individuals with social phobia 
assume that others are fundamentally critical and are likely to evaluate them negatively in social 
situations. Furthermore, individuals with social phobia tend to attribute significant importance to being 
perceived positively by others. Thus, the model suggests that individuals with social phobia generally 
overestimate the probability and costs of performing poorly in social situations and/or being negatively 
evaluated by others.  Rapee & Heimberg (1997) identified a number of cognitive and behavioral 
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processes that are thought to contribute to the development and maintenance of social anxiety, 
including selective attention to external indicators of negative evaluation (i.e., frowns, signs of 
boredom). Selective attention to negative cues is thought to contribute to increased behavioral and 
physical symptoms of anxiety, as well as additional misperceptions about how one is seen and perceived 
by others. A recent extension of Rapee & Heimberg’s (1997) social anxiety disorder model highlights 
imagery as an important component of SAD; the updated model posits that negative images of past 
social failures contribute the development and maintenance of SAD by increasing anxiety the amount of 
anxiety experienced in anticipation of and during social exposures,  as well as by increasing expectations 
for negative outcomes (Heimberg, R. C., Brozovich, F. A., & Rapee, R. M., 2010).The models described 
above have laid a foundation for the development of cognitive behavioral therapies for social phobia. 
Cognitive interventions generally focus on cognitive processes that impact social phobia. For example, 
socially anxious individuals often believe that, (1) their social behavior is much more inept than it 
actually is, (2) their physical symptoms of anxiety are much more apparent to others than they actually 
are, (3) others perceive them more poorly than they actually do, and (4) the negative consequences or 
costs of their inept behavior are much more dire than they actually are. Interventions are designed to 
challenge and modify these distorted patterns of thinking. Behavioral interventions are based on 
modern accounts of learning theory, and typically involve some form of exposure to the feared stimulus. 
More specifically, exposure therapy involves repeated confrontation of a feared stimulus, in the absence of 
a negative/feared outcome, resulting in diminished fear. 
1.1.2 Treatments for Social Phobia 
 The empirical literature supports the efficacy of cognitive-behavioral therapy (CBT) (Antony & 
Barlow, 1997; Heimburg & Juster, 1995; Turner, Cooley-Quille, & Beidel, 1996). CBT interventions for social 
phobia incorporate various components, including cognitive therapy, anxiety management training, 
exposure-based strategies, and social skills training. Furthermore, CBT interventions for social phobia 
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can be effectively delivered in both group (Heimberg, et al., 1990; Rodebaugh, et al., 2004) and 
individual (Wells & Papageorgiou, 2001) formats. Two group interventions cognitive behavioral group 
therapy (CBGT; Heimberg, Dodge, Hope, & Kennedy, 1990) and exposure group therapy (EGT; Hofmann, 
2002) have been associated with positive empirical and clinical outcomes. CBGT  has received the most 
empirical support and is currently considered the “gold standard” treatment for social phobia 
(Heimberg, 2002; Rodebaugh, Holaway, & Heimberg, 2004).  
Individual and group cognitive behavioral treatment packages for social phobia have typically 
relied on in vivo and/or imaginal exposure techniques; in fact, there is an extensive body of literature 
supporting in-vivo exposure as the treatment of choice for specific phobias (Barlow et al., 2002). 
Although these methods of exposure have proven to be effective, they are also associated with a 
number of drawbacks. For example, in-vivo (real world) exposure techniques can pose challenges such 
as cost, time demands, and threats to confidentiality. Lack of control is another area of concern, as 
clinicians have little-to- no control over outcomes that occur in the context of real world exposure to the 
feared stimuli. Imaginal exposure addresses some of the challenges of in-vivo exposure, but not without 
posing its own challenges. Most notably, some individuals have difficulty imagining the feared stimulus. 
Virtual reality exposure therapy (VRE) involves confrontation of feared stimuli within a virtual 
environment, and literature suggests that VRE is an effective medium for conducting exposure therapy. 
VRE interactive environments typically involve the use of a head-mounted display through which the 
virtual world is viewed. Head-mounted displays consist of separate display screens for each eye, along 
with some type of display optics, stereo headphones, and a head tracking device. The perspective on the 
virtual world changes according to the user’s natural head movements and body motion. To date the 
most extensive and methodologically sound research supporting the efficacy of VRE stems from 
treatment outcome studies for fear of flying (Rothbaum et al., 2002) and agoraphobia (Botella et al., 
2007). Emotional processing theory (Foa & Kozak, 1996) has served as theoretical foundation to support 
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the use of VRE. According to this theory, the following two conditions are essential in order for exposure 
to be successful (1) the fear structure must be activated and (2) information that is not compatible with 
the existing structure must be presented and incorporated. VRE engages various sensory modalities 
(audio, visual, interoceptive) through which it is able to activate the fear structure. Thus, because it 
provides a medium through which: (1) the fear structure can be activated and (2) incompatible 
information can be integrated into the existing structure, theory suggest that VRE may be a promising 
and effective alternative to in-vivo and imaginal exposure.   
 Initial findings from empirical studies examining VRE in the treatment of social phobia are 
promising. For example, Anderson et al., (2005) conducted the first open trial of VRE (N = 10) for social 
phobia, using virtual environments to create public speaking scenarios;  they found that participants 
receiving VRE rated themselves as significantly improved on fear of public speaking measures at the 
conclusion of treatment. Next, Klinger, Bouchard, et al. (2005) evaluated the efficacy of VRE in 
comparison to group CBT in a sample of individuals (N = 36) with social phobia; post-treatment findings 
indicated that individual VRE and group CBT were equally effective at reducing symptoms of social 
phobia.  Wallach and colleagues (2009) explored VRE in the treatment of social phobia (N = 88) during 
which they compared CBT alone to CBT plus VRE versus a wait list control. Findings indicated that CBT 
was as effective as CBT plus VRE; further both treatments were superior to the waitlist condition. 
Interestingly, twice as many participants dropped out of the CBT condition than dropped out of CBT plus 
VRE (Wallach et al., 2009).  
In addition to CBT treatments, the empirical literature supports the use of a number of 
pharmacological interventions for social phobia, including benzodiazepines, selective serotonin reuptake 
inhibitors (SSRI’s), monoamine oxidase inhibitors (MAOIs), and beta-adrenergic blockers. SSRI’s are 
often considered to be the most appropriate first line of pharmacological treatment for generalized 
social phobia because they are relatively safe and generally well-tolerated. Several controlled double-
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blind trials have yielded evidence supporting the superiority of SSRI’s including fluvoxamine (Stein, Fyer, 
Davidson, Pollack, & Wiita, 1999), sertraline (Van Amerigen et al., 2001), and paroxetine (Baldwin, 
Bobes, Stein, Scharwachter, & Faure, 1999) over placebo medications, in the treatment of social phobia.  
Another class of medications commonly prescribed in the treatment of social phobia is non-selective 
beta blockers, such as propranolol. Propranolol was originally developed and prescribed for the 
treatment of hypertension. However, because of its pharmacodynamic properties, propranolol is also 
effective in reducing symptoms of autonomic arousal (i.e., tachycardia, palpitations, and tremor) for 
individuals with social phobia (Hansen et al., 2008). Finally, phenelzine is in a class of medications called 
monoamine oxidase inhibitors (MAOIs). Findings from a randomized, double blind trial revealed that 
phenelzine was associated with positive treatment outcomes, including reductions in avoidance and 
anxiety for individuals with social phobia (Liebowitz, et al., 1992).  
Although they are sometimes prescribed in the absence of other treatment interventions, 
medications for social phobia are commonly given in conjunction with other cognitive and behavioral 
interventions, such as exposure therapy. Concurrent use of medication during exposure therapy is 
thought to increase the likelihood that individuals will engage in treatment by making exposures less 
aversive and more tolerable. Findings from previous treatment outcome studies comparing combined 
treatment (medication plus CBT) to CBT treatment alone have yielded mixed results. For example, 
Heimberg and colleagues (1998) compared the efficacy of phenelzine, CBGT, their combination, and a 
pill placebo in the treatment of social phobia. Post-treatment findings indicated that combined 
phenelzine and CBGT was more superior to placebo than either CBGT or phenelzine alone (Heimberg, et 
al., 2002). Contrastingly, findings reported by Davidson et al. (2004) indicated that both CBT and 
fluoxetine are superior to pill placebo according to post-treatment measures of social phobia, but that 
there was no advantage to combining CBT with fluoxetine (Davidson et al., 2004).  Thus, whether used 
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alone or in combination with other cognitive and behavioral treatments empirical findings have 
supported the value of pharmacological interventions for social phobia.   
In summary, previous findings support the efficacy of various cognitive behavioral and 
pharmacological interventions in the treatment of social phobia. Despite the strong evidence that these 
interventions are efficacious at post-treatment, as detailed below, we know less about the long term 
maintenance of social phobia treatment gains. 
1.2 Long-term Outcomes in the Treatment of Social Phobia 
As a whole, social phobia treatment outcome studies have been limited in terms of the extent to 
which they have examined long term treatment gains. This limitation was first highlighted by Heimberg 
(1989) when his review of seventeen treatment outcome studies for social phobia revealed an average 
follow-up length of 5.12 months. Fortunately, a more recent review indicated that research in this area 
is advancing; Acarturk et al. (2009) identified nine long-term studies with follow-up periods ranging from 
seven to eighteen months. Given the chronic and often debilitating nature of social phobia, however, it 
is important to continue to seek additional insight about how individuals fare in the longer term after 
completing treatment. Existing literature on long-term treatment outcomes for social phobia will be 
reviewed in the following section. For the purposes of this discussion “long term” outcome will refer to 
studies that included follow-up assessments that occurred at least two years after the completion of 
treatment.  
Heimberg and colleagues (1993) conducted the first and perhaps most methodologically sound 
long-term follow-up study of social phobia treatment to date. Participants (N = 40) in the original 
treatment outcome study (Heimberg et al., 1990) included a sample of individuals meeting diagnostic 
criteria for generalized social phobia who were randomly assigned to and completed either cognitive 
behavioral group therapy (CBGT) or educational-supportive therapy (EST). Post-treatment findings 
revealed significant improvements for both groups, with CBGT being superior to EST on most outcome 
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measures (Heimberg et al., 1990).  Later, Heimberg and colleagues (1993) assessed long-term outcomes 
of CBGT and EST via a battery of self-report measures, an individualized behavioral test, and a structured 
interview which was administered by an independent assessor. Participants (N = 19) in the follow-up 
study were assessed 4.5 to 6.25 years after completing treatment. Long-term-follow-up findings, across 
all assessment modalities, revealed that CBGT post-treatment gains were maintained and that CBGT 
participants continued to exhibit significantly fewer social phobia symptoms than EST participants at 
long-term follow-up. Heimberg et al. (1993) further characterized their findings in terms of clinically 
significant improvement (e.g., treatment response); 67% of long-term follow-up completers were 
classified as significantly improved after having shown a two point decrease and an end-point score of 
three or less (suggesting no further treatment needed) according to observer ratings on the Clinician’s 
Severity Rating Scale (DiNardo et al., 1983). It is important to note, however, that the sample of long-
term-follow-up completers differed significantly from the original treatment sample in terms of pre-
treatment and six-month follow-up symptom severity. Therefore, Heimberg and colleagues (1993) 
ultimately concluded that, “CBGT is an effective long-term treatment for socially anxious individuals who 
are initially less impaired”.  
Fava et al. (1989) investigated the efficacy of an outpatient “homework-exposure” based 
protocol in the treatment of individuals with generalized social phobia. Post-treatment findings 
indicated that forty-five (64%) participants no longer met DSM-IV criteria for social phobia.  Long-term 
follow-up participants (N = 45) were individuals who were considered to be in remission, as defined by 
no longer meeting diagnostic criteria for social phobia and being rated as “much better” according to 
Kellner’s Global Rating of Improvement (1972), at post-treatment. Findings revealed that 98% of 
participants were still in remission two years after treatment and 85 % of participants remained in 
remission at 5-year and 10-year follow-up (Fava et al., 2001). In sum, these findings yielded evidence 
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supporting the long-term maintenance of treatment gains for an individual, homework-based social 
phobia treatment protocol. 
Two studies have examined the long-term efficacy of internet-delivered cognitive therapy for 
social phobia. Hedman et al. (2011) examined long-term outcomes of internet-based CBT at one year (N 
= 71) and at five years (N = 71) after treatment had ended. Primary outcome measures included the 
Liebowitz Social Anxiety Scale (LSAS), the Clinical Global Impression of Improvement (CGI-I; Guy, 1976) 
scale, and the Structured Clinical Interview for the DSM-IV-TR (SCID; 2002).  Results revealed significant 
improvements from post-treatment to one year follow-up which were sustained five years after the 
completion of treatment. The researchers defined clinically significant change in terms of diagnostic 
status and clinician ratings on the CGI-I, with 48% of participants no longer meeting diagnostic criteria 
and 64% being rated as “much improved” on the CGI-I at five year follow-up. Similarly, in Carlbring et 
al.’s (2009) 2.5 year follow-up of internet-delivered CBT participants (N = 44) demonstrated significant 
improvements, according to self-report ratings of social phobia, from pre-treatment to post-treatment 
as well as from post-treatment to 30 month follow-up indicating that treatment gains were not only 
maintained but also improved upon during the follow-up period.  
Willutski et al. (2012) examined the long-term efficacy of manualized cognitive therapy and 
combined resource oriented cognitive behavioral therapy (ROCBT), which seeks to build upon a patient’s 
existing resources by highlighting past successes in treatment.  More specifically, ROCBT therapists focus 
on the activation, clarification, and use of exceptional situations (e.g., situations when the problem was 
less strongly pronounced or when the individual behaved in accordance with his/her goals). Outcomes 
were measured via participant (N = 27) ratings on the Social Phobia Scale (SPS; Mattick & Clarke, 1998), 
Social Interaction Anxiety Scale (SIAS; Mattick & Clarke, 1998), Fear of Negative Evaluation (FNE; Watson 
& Friend, 1969), and the Social Avoidance and Distress Scale (SAD; Watson & Friend, 1960); no 
behavioral or clinician rated measures were used. Findings, based on self-report ratings, revealed that 
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long-term follow-up participants had not only maintained post-treatment gains at ten year follow-up but 
had also made significant improvements over the course of the follow-up period on two of four the 
primary self-report, social phobia outcome measures; this finding held true even after individuals who 
reported receiving additional treatment (26%) during follow-up were excluded from the analyses.  
Next, Mortberg, Clark, & Bejerot (2011) conducted a five-year follow-up of individuals who had 
participated in their randomized clinical trial (Mortberg et al., 2007) comparing the efficacy of Intensive 
Group Cognitive Therapy (IGCT) to Individual Cognitive Therapy (ICT) in the treatment of social phobia. 
Follow-up measures included a battery of self-report measures, including the FNE, LSAS, and the SCID 
which was administered by an independent assessor. Results indicated long-term follow-up participants 
(N = 48) had maintained and improved upon post-treatment gains at long-term follow-up according to 
self-report ratings of social anxiety. Moreover, 74% of participants (n = 29) who completed the SCID at 
long-term follow-up no longer met diagnostic criteria for social phobia.  
Two studies have examined long-term outcomes of social skills based treatment interventions 
for social phobia.  Turner, Beidel, and Cooley-Quille (1995) examined the long –term effectiveness of 
Social Effectiveness Therapy (SET); SET is reported to include psychoeducation, social skills training, in 
vivo and/or imaginal exposure, and programmed practice. Post-treatment findings suggested that the 
majority (84%) of participants (N = 13) reported moderate to high rates of improvement. Long-term 
follow-up results indicated that treatment gains were maintained two years after treatment had ended 
for long-term follow-up participants (N=8). Furthermore, findings revealed a significant difference 
between post-treatment and follow-up self-reported fear symptoms indicating that participants 
continued to improve during the follow-up period, after treatment had been ended. Stravynski et al. 
(2000) evaluated the long-term maintenance of a behavioral group intervention which focused 
specifically on improving social skills and interpersonal functioning. Initial findings revealed that all 
treatment completers (N=4) had improved to the extent that they no longer met diagnostic criteria for 
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social phobia by six month follow-up. Moreover, long-term follow-up participants (N=4) had maintained 
gains and continued to not meet criteria for social phobia at two year follow-up. 
While findings have generally been promising, researchers examining long-term outcomes of 
social phobia interventions have also identified shortcomings in the current body of literature. For 
example, some of these studies are characterized by small sample sizes [Turner et al., 1995 (N = 8, 62% 
of treated sample); Heimberg et al., 1993 (N = 19, 48% of treated sample); Stravynski et al., 2000 (N = 4, 
100% of treated sample)]. Related, response rates have varied greatly across studies with some 
reporting rates as low as 31% (Willutski et al., 2012; N = 27) while others have reported rates as high as 
89% (Hedman et al., 2011; N = 71).  Additionally, some research has relied solely on self-report 
measures (Willutski et al., 2012). Next, in some studies, the follow-up sample differed significantly from 
the original sample of treatment completers (Heimberg et al., 1993; Fava et al., 2001). For example, 
Heimberg et al.’s (1993) sample of follow-up completers reported significantly fewer symptoms of social 
phobia at pre-treatment and six month follow-up than did individuals who did not complete the long-
term follow-up.  Selection bias is another methodological limitation of previous literature long-term 
follow-up investigations of homework based exposure (Fava et al., 2001) and interpersonal-focused 
behavioral group therapy (Stravinsky et al., 2000) were limited to individuals who were in  remission at 
post-treatment. 
In summary, although existing literature regarding the long-term maintenance of treatment 
gains for social phobia is not without its shortcomings, as a whole, CBT interventions have generally 
yielded positive long term outcomes. The long-term maintenance of CBT treatment gains is not 
surprising given that CBT approaches to therapy are designed to provide individuals with the training 
and skills needed to function as their own therapists so that they are able to continue to apply what 
they have learned in therapy in “real world” settings after therapy is finished (Beck, 1995).  
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1.2.1 Long-term Outcomes of Virtual Reality Exposure Therapy 
Safir and colleagues (2012) conducted the only long-term follow-up study of a randomized 
clinical trial testing VRE for social fears—findings from this study, based on participants’ self-report 
ratings, revealed that socially fearful individuals generally maintained VRE post-treatment gains at one 
year follow-up (Safir et al., 2012). Outside of the social phobia literature, Wiederhold and Wiederhold 
(2003) explored the long-term efficacy of VRE for fear of flying (FOF) and found that VRE treatment gains 
were maintained at 3-year follow-up. Additionally, Rothbaum and colleagues (2000; 2002) examined the 
efficacy of VRE and standard in vivo exposure therapy for FOF; findings indicated that treatment gains 
were maintained at 6-month and 12-month follow-up for both treatment groups (Rothbaum et al., 
2002). These findings were replicated with a larger sample (N=75) with identical results, including long-
term follow-up (Rothbaum et al., 2006). Interestingly, subsequent research suggests that many of the 
participants who completed treatment during the original outcome studies continued to maintain or 
improve upon gains made during treatment, even in the aftermath of a catastrophic fear-relevant event, 
the September 11, 2001, terrorist attacks (Anderson, Jacobs, Linder, Edwards, Zimand, et al., 2006). 
1.2.2 Long-term Outcomes of Pharmacological Interventions 
There is a strong body of literature indicating that medication alone and in combination with 
other CBT treatments for social phobia is associated with increased rates of improvement at post-
treatment (Liebowitz, 1999; Clark, 2003). However, long-term follow-up data suggest that these positive 
outcomes are generally not well maintained following the discontinuation of medication. For example, 
post-treatment results from a randomized controlled trial indicated that phenelzine (an MAOI) was not 
only superior to placebo, but also was associated with more rapid response rates than CBGT during 
treatment (Heimberg, 1998). However, when the researchers examined relapse rates at 6 month follow-
up, they found that 33% of those previously treated with phenelzine had relapsed, while none of those 
previously treated with CBGT had relapsed (Liebowitz et al., 1999).  Next, Blomhoff and colleagues 
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(2001) found that sertraline (an SSRI) outperformed exposure therapy in a primary care sample of 
individuals with social phobia at post-treatment. Nevertheless, twelve month follow-up data suggested 
that participants treated with exposure continued to improve during the follow-up period, while those 
treated with sertraline alone, or in combination with exposure treatment, tended to deteriorate after 
treatment was terminated (Haug et al., 2003). Concomitant use of benzodiazepines during exposure 
treatment for social phobia also has been associated with higher rates of relapse (Fava et al., 2001). 
Thus, there is a strong body of literature suggesting that relapse rates after the discontinuation of 
effective pharmacotherapy treatments are significantly higher than relapse rates following the 
successful discontinuation of CBT. In addition to these findings, theoretical perspectives and empirical 
research regarding the role of extinction learning in exposure therapy suggest that pharmacotherapy 
may attenuate responses to CBT for social phobia. In the next section, we review the theoretical 
foundations of exposure therapy before discussing the potential impact of pharmacological 
interventions on exposure.  
1.2.3 Theoretical Foundations of Exposure Therapy 
Exposure therapy involves repeated confrontation of a feared stimulus in the absence of a 
negative/feared outcome, resulting in diminished fear. Researchers have examined and identified several 
mechanisms through which exposure therapy is thought to decrease fear and anxiety. Research in this area 
has relied heavily on learning theory principles of classical and operant conditioning. According to classical 
conditioning theory, fear develops through the following process: (1) repeated pairing of a previously 
neutral stimulus with an unconditioned stimulus that innately evokes discomfort or fear; (2) causing the 
neutral stimulus to become associated with aversive properties to the extent that it ultimately (3) 
becomes a conditioned stimulus that elicits an anxiety response, on its own, in the absence of the 
unconditioned stimulus (Pavlov, 1927; Rescorla & Wagner, 1972). Operant conditioning theory is based 
on the principles of reinforcement and punishment whereby reinforcement increases the frequency of a 
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targeted behavior while punishment decreases the frequency of a behavior (Skinner, 1938).  Mowrer’s 
two-stage model (1939, 1960) represents one of the first significant attempts to elucidate the mechanisms 
underlying fear acquisition and exposure therapy. Mowrer suggested that fears are acquired through 
classical conditioning and maintained through negative reinforcement (i.e., avoidance of the feared stimulus 
is reinforced as a result of decreased fear/anxiety). In the context of Mowrer’s theory, exposure is thought 
to directly reduce avoidance behaviors and abolish learned fear via direct confrontation of the feared 
stimulus. Critics of Mower’s theory have cited lack of synchrony among the components of fear responding 
(i.e., subjective self-report, physiological arousal, and avoidance behavior) as evidence to refute a direct 
causal link between fear and avoidance (Rachman, 1976).  
 Fear reduction during and after exposure therapy also has been attributed to the process of 
habituation. Habituation is defined as a “decrement in response as a result of repeated stimulation” 
(Thompson & Spencer, 1966, p.17). Tryon (2005) highlighted additional defining features of habituation, 
including : (1) prolonged exposure leads to decreased fear over time; (2) a dishabituated (fear) response 
is inevitable in the absence of exposure; (3) the habituated response (decreased fear) returns quickly in 
the presence of additional exposure; and (4) reduced fear responses are not attributed to new learning. 
As reviewed by Moscovitch, Antony, & Swinson (2009) , the following clinical observations and empirical 
findings are cited as evidence against habituation theory:  (1) individuals do not always experience 
decreased anxiety even after lengthy exposure; (2) contrary to the notion that dishabituated responses 
occur in the absence of exposure, relapse rates after exposure therapy are far less than 100%; and (3) 
relapse periods are not always transient—experiences of fear do not always diminish quickly even in the 
presence of additional exposure (i.e., booster sessions).  
More recently developed theories purport that extinction is the primary mechanism through which 
exposure therapy leads to decreased fear and anxiety. Extinction is described as process of new, active 
learning that occurs with repeated, systematic confrontation of a feared or conditioned stimulus (i.e., 
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speaking in front of others) in the absence of an unconditioned stimulus (i.e., bad outcome) (Rescorla, 
2001). According to extinction theory, through the experience of repeated pairings of the CS in the 
absence of the US (i.e., exposure therapy) individuals will begin to attribute new meanings to the CS. For 
example, in the case of speaking anxiety, exposure therapy sets the stage for learning, such that a new 
association between public speaking and safety (absence of a bad outcome) develops. Rather than 
eliminating negative associations that existed prior to treatment, new associations (meanings) between 
the CS (speaking in public) and safety learned during exposure therapy come into co-existence with the 
negative associations that existed before treatment. Thus, when confronting the CS (public speaking) 
after successful exposure therapy, individuals must choose between two competing meanings of the CS 
(1) fear, something bad will happen or (2) safety. In sum, extinction theory purports that new associative 
learning mediates the relationship between exposure and fear reduction. 
1.2.4 Potential Impact of Pharmacological Interventions on Exposure 
Extinction learning is heavily dependent on context, and thus it is imperative that the context in 
which the feared stimulus is presented during exposure therapy matches the context in which the fear 
cue is likely to be confronted after treatment has ended. Within this framework, relapse is described as 
a persistence of the original conditioning events in memory (public speaking—bad outcome) that are 
reactivated by contexts other than those that are associated with successful exposure therapy. The 
notion of context dependent learning is evocative of  the concept of state dependent learning (SDL), 
which occurs when learning acquired in one context is not retrievable in a different context (Overton, 
1991). SDL is an important concept to consider when pharmacological interventions serve as an adjunct 
to exposure therapy in the treatment of social phobia. Given the context-dependent nature of extinction 
learning during exposure therapy, SDL may occur when combined treatment methods (medication plus 
therapy) are implemented in the treatment of anxiety disorders. According to proponents of SDL , “if the 
medicated state serves as a context for learning during exposure therapy, treatment gains could 
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potentially be lost following drug discontinuation” (Morissette, Spiegel, & Barlow, 2008, p.211). To 
illustrate, a person receiving VRE for social phobia while taking an SSRI, who completes psychotherapy 
and then subsequently discontinues the SSRI may encounter difficulties (return of symptoms) as a result 
of having to retrieve safety memories in a different context (no medication) other than the context in 
which safety memories were developed during VRE (with medication). Consistent with SDL theory, 
research examining the treatment of panic disorder (Marks et al., 1993) and fear of flying (Wilhelm & 
Roth, 1997) has yielded evidence to suggest that concurrent use of medication during exposure therapy 
may interfere with short term and long term treatment outcomes. Whereas little is known about the 
role of SDL from a social phobia treatment outcome perspective, preliminary findings (Morissette et al., 
2008) suggest that additional research in this area is warranted.  
Morissette, Spiegel, & Barlow (2008) conducted the first empirical study designed to explore SDL 
within the context of combined exposure and pharmacotherapy in the treatment of social phobia. 
Participants included (N=4) individuals meeting diagnostic criteria for social phobia who engaged in a 
series of situational exposures while taking either alprazolam (.75mg), propranolol (40mg), placebo, or 
no medication. Next, forty-eight hours after engaging in the original exposure exercise, participants 
were asked to engage in the same situational exposure in the absence of medication. This design 
allowed the researchers to examine the retention of learning after a shift in context (i.e., medicated 
versus non-medicated). Findings indicated that participants were more likely to maintain treatment 
gains following situational exposures that occurred in the absence of concurrent medication. More 
specifically, participants who encountered exposure treatment in the same context (non-medicated) in 
which the feared stimulus was encountered at follow-up (non-medicated) were more likely to report 
long-term treatment gains and thus these findings provided additional support for the notion of SDL. 
Other pharmacokinetic properties of anxiety medications and their effects on exposure 
treatments have been considered as well. For example, some have theorized that anxiety medications, 
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such as propranolol, may inhibit the new (extinction) learning that is thought to occur during exposure 
therapy because of its pharmacokinetic properties. One of the primary actions of propranolol is to 
inhibit norepinephrine, a neurotransmitter that is thought to enhance memory consolidation. Previous 
findings have shown that individuals given propranolol immediately after a traumatic experience show 
less severe symptoms of PTSD compared to their respective control groups that did not receive the drug 
(Vaiva et al., 2003). These findings support the notion that propranolol may interfere with memory 
consolidation in the aftermath of a traumatic event. While propranolol’s supposed hindrance of memory 
consolidation can be conceptualized as a positive outcome in the case of trauma (lessens the likelihood 
of intrusive, unwanted post-traumatic memories), decreased memory consolidation during exposure 
therapy for social phobia is likely to be associated with negative outcomes. Furthermore, because 
extinction learning thought to occur during successful exposure therapy involves the consolidation of 
new memories, there is reason to believe that concurrent use of propranolol may also interfere with 
exposure based interventions for social phobia.  In summary, research and theory has identified several 
mechanisms that are thought to account for response to exposure therapy, including theories of state 
dependent and extinction learning.  Additional research in this area is needed in order to further 
understand the extent to which theories of SDL and extinction learning may or may not account for 
combined CBT and pharmacological treatment outcomes for social phobia. 
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2     CURRENT STUDY 
2.1 Objectives 
The present study sought to examine the extent to which cognitive-behavioral treatment gains 
for social phobia are maintained in the long-term, after treatment has ended using a multi-modal 
assessment approach.  A secondary aim was to examine whether concurrent use of medication during 
treatment attenuates long-term responses to exposure therapy. The specific hypotheses are as follows: 
2.2 Hypotheses 
Hypothesis 1: Treatment completers will exhibit fewer social phobia symptoms at long-term 
follow-up, relative to pre-treatment, as assessed by self-report and behavioral measures.  
Hypothesis 2: Post-treatment gains will be maintained over the long-term follow-up period for 
individuals who completed treatment.  
Hypothesis 3: Concurrent medication use, during treatment, will be associated with diminished 
treatment gains at long term-follow-up for individuals who have discontinued medication during the 
follow-up period. 
2.3 Methods 
The present study was a long-term follow-up of two larger social phobia treatment studies. The 
first study (Anderson, Price, Edwards, Obasaju, et al., 2013) was funded by the National Institutes of 
Mental Health (NIMH) and compared Exposure Group Therapy and Virtual Reality Exposure Therapy for 
social phobia to wait-list controls using a randomized, controlled design. The second study was funded 
by the Anxiety Disorders Association of America and examined amygdala activity as a predictor of 
treatment response to VRE using functional magnetic resonance imaging, in an uncontrolled trial with a 
small sample. For the purposes of the current long-term follow-up, the procedures for the parent 
studies were the same, with the exception that participants in the fMRI study were not randomly 
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assigned to treatment; they all received VRE. Figures 1 and 2 were prepared in accordance with 
guidelines outlined in the CONSORT (Consolidated Standards of Reporting Trials; Altman, et al., 2001) 
and TREND (Transparent Reporting of Evaluations with Nonrandomized Designs; Des Jarlais, Lyles, 
Crepaz, 2004) statements. The figures show the flow of participants through the two treatment studies.  
Eligible participants for the two parent studies were English speaking individuals who met DSM-
IV (APA, 2000) criteria for a primary diagnosis of social phobia, as assessed by the Structured Clinical 
Interview for the DSM-IV (SCID; First, Gibbon, Spitzer, & Williams, 2002), with a predominant fear of 
public speaking. Individuals on psychoactive medication were required to be stabilized on their current 
medication(s) and dosage(s) for at least 3 months and were to remain at the stabilized dosage 
throughout the course of the study. Individuals meeting any of the following criteria were excluded, (a) 
history of mania, schizophrenia, or other psychoses; (b) recent suicidal ideation; (c) current alcohol or 
substance dependence; (d) inability to tolerate the virtual reality helmet/environment; (e) history of 
seizures. Recruitment methods included newspaper advertising, posted flyers, internet based outlets, as 
well as referrals from local area professionals and other study participants.  
2.3.1 Participants - Eligible for Long-term Follow-up  
Taken together the two parent studies yielded a treated sample (N = 75) of individuals who had 
completed either VRE (n = 42; 56%) or EGT (n = 33; 44%) for social phobia.  The treated sample included 
individuals with a primary diagnosis of either generalized (n = 34; 45.3%) or non-generalized social 
phobia (n = 41; 54.7%). Participants ranged in age from 19 to 69, with an average age of 40 (SD = 11.62). 
Study participants self-identified as “Caucasian” (n = 39), “African-American” (n = 21), “Latino” (n = 4), 
Asian American (n = 3), Chinese (n = 1), Eritrean American (n = 1), Arabic (n = 1), African (n = 1), Biracial 
(n = 2), and “other-not specified” (n = 2). For the most part, treatment completers were well educated, 
with 67% attaining an undergraduate degree or higher. Finally, 51% of the treated sample reported their 
relationship status as married.  
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The projects were approved by the Institutional Review Board of Georgia State University. 
Eligibility for the parent studies was determined through a two part process consisting of a brief 
telephone screening and a subsequent in-person, pre-treatment assessment.  After expressing interest 
and consenting to complete a telephone screening, study candidates completed a short phone interview 
to determine their initial eligibility. Initial telephone screenings were conducted by doctoral level 
students in the clinical psychology program at GSU and consisted of a series of questions related to 
mood, anxiety, and substance use. Those who were not excluded during the telephone screening were 
given the opportunity to participate in an in-person, pre-treatment assessment at Georgia State 
University. Consent was obtained prior to the pre-treatment assessment as well. The pre-treatment 
assessment included a structured diagnostic clinical interview (SCID-IV), administered by a doctoral 
student, a behavioral avoidance task, and a battery of self-report measures. Eligible Study 1 (FOPSII) 
participants were randomly assigned to VRE, EGT, or WL.  Eligible Study 2 (FMRI) participants were all 
assigned to VRE. 
2.3.2 Assessments  
During the pretreatment assessment, participants met with a doctoral student in clinical 
psychology.  The SCID was administered to determine if the participant met criteria for social anxiety 
disorder and other comorbid disorders. Assessors were trained and supervised by a licensed clinical 
psychologist. Furthermore, all diagnostic assessments were videotaped and a randomly selected subset 
were reviewed by a licensed psychologist to calculate the inter-rater reliability (100% agreement for 
primary diagnosis). In addition, participants were asked to complete a behavioral avoidance task (BAT) 
during the pretreatment assessment and then again after completing treatment. The pretreatment and 
post-treatment BATs were optional, they did not impact study eligibility or treatment participation. It 
was ensured that participants received different topics at pre-and post-treatment. BAT speeches were 
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videotaped and were conducted in front of audiences that consisted of between one and three 
members of the research staff.  
Also, the three month follow up was conducted in person and consisted of completion of the full 
battery of self-report measures. The SCID was used, at three month follow-up, to reassess the diagnostic 
status endorsed during the pre-treatment assessment.  All pre-treatment and follow-up assessments 
were conducted by doctoral students who were blind to the type of treatment received.  For the 12 
month follow up assessment, participants were mailed the full battery of self-report measures and 
asked to complete and return them via provided, self-addressed stamped envelopes. Compensation was 
provided to participants who completed the self-report battery of measures administered at post-
treatment, three, and 12 month follow-up.  
2.3.3 Treatment 
Prior to administering therapy study therapists attended two-day intense training workshops, 
led by the developers of the respective treatments. Each of the study therapist also received weekly 
supervision by the primary investigator of the study.  Ratings of treatment integrity and competence 
were completed, by the developers of the respective treatments, for a randomly selected subset of the 
sessions.  
 The VRE and EGT treatment groups were designed to be as similar as possible, with the 
exception of the modality for the delivery of exposure. Both treatments specifically targeted public 
speaking fears and relied on exposure therapy as the primary intervention for treating social phobia. The 
two treatments included cognitive restructuring exercises and video-taped feedback. Both treatments 
sought to address specific aspects of social phobia identified in psychopathology literature, including 
self-focused attention, distorted perceptions of self and others, perceptions of emotional control, 
rumination, and realistic goal setting for social situations. Also, both treatments consisted of eight 
therapy sessions conducted over a period of approximately eight weeks. The mechanism and setting 
22 
through which exposure was delivered varied for each of the two treatment groups.  Individual study 
therapists relied on the virtual environment (VRE) to facilitate exposure to public speaking fears, while 
group therapists relied on other group members (EGT) to help facilitate exposure. 
Virtual reality exposure (VRE) was implemented according to a manualized treatment protocol 
and was administered individually by either a licensed clinician or an advanced doctoral student in the 
clinical psychology program.  During session one, participants were introduced to the VRE treatment 
rationale and taught how to identify and rate their anxiety on a subjective units of discomfort scale 
(SUDS). Breathing training also was introduced. Session two began with a review of the treatment 
rationale and otherwise focused on teaching the concept of cognitive restructuring, including its 
purpose and practice. Session three focused on self-perceptions during public speaking. During this 
session, participants reviewed video of their pretreatment speeches and were asked to compare how 
anxious they looked on the video to how anxious they rated themselves while giving the speech. Session 
four focused on identifying the role that both safety behaviors and self-focused attention can play in the 
maintenance of social phobia. Participants were first videotaped demonstrating their most commonly 
used safety behaviors while giving a prepared talk. Next, participants were instructed to focus their 
attention on the audience and to refrain from using safety behaviors while they were being videotaped 
giving the same talk. Then, participants were able to observe the two videos to see how their 
performances differed when they focused on the audience while giving their talk versus when they 
engaged in safety behaviors and self-focused attention while speaking.  
Exposure exercises were conducted during sessions five through eight using the virtual 
audience. During VRE exposure exercises participants were fitted with a head mounted display , that 
contained screens for each eye, stereo headphones and a head tracking device, through which they 
were exposed to one of three virtual environments. VR exposure environments included a virtual 
conference room (~5 audience members), a virtual classroom (~35 audience members), and a virtual 
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auditorium (appearance of 100+ audience members). VRE therapists had the ability to manipulate the 
reactions of the audience in a number of ways including making them appear interested/bored, 
supportive/hostile, distracted (i.e., cell phone ringing), as well as the ability to manipulate the difficulty 
of questions that were posed by the audience. Virtual environments were manipulated according to the 
client’s goals for treatment and their pre-constructed fear hierarchy. Participants were exposed to each 
item on their hierarchy until their reported fear was reduced by 50 percent before being exposed to 
their next item on the hierarchy. Treatment concluded with a review of the different anxiety 
management and relapse prevention strategies.   
Exposure group therapy (EGT; Hofmann, 2002) consisted of eight group sessions of manualized 
treatment over a period of eight weeks which were co-led by a licensed clinical psychologist and an 
advanced doctoral student.  Groups consisted of up to five participants. During session one, participants 
were introduced to the EGT treatment rationale, including the theoretical basis for exposure therapy. 
Session two began with a review of the treatment model, participants were then asked to engage in 
their first exposure exercise which consisted of giving a brief speech about the social phobia treatment 
models in front of the group. Furthermore, self-perceptions were addressed in session two and video 
from each client’s treatment model speech was used as a mechanism to help participant’s highlight 
discrepancies between how anxious they appeared on video to how anxious they rated themselves prior 
to viewing the video. Group members were also asked to provide each other with positive feedback 
when the videotaped speeches were reviewed. Sessions three through six followed a similar model to 
that of session two. Session seven includes real-world exposure exercises. During this session 
participants exited the lab to engage in social mishap exercises on the Georgia State University Campus. 
The social mishap exercises provided participants with opportunities to evaluate their beliefs about 
social threats and costs, by intentionally engaging in flawed social behaviors in a real world setting, 
while still in the presence of continued support from other group members/therapists. The final session 
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provided participants with tools to prevent relapse and included a review of what was learned over the 
course of therapy.   
 In addition, Study 1 included a wait list condition which lasted eight weeks after which 
participants completed a battery of post WL questionnaires similar to the battery that is administered 
after both the EGT and VRE treatments. Then, WL participants were randomly assigned to either VRE or 
EGT and received the same 8 week treatment protocol described above. 
Ratings of adherence in delivering the EGT and VRE protocols were provided by the developers 
of the respective treatments for a randomly selected subset of videotaped sessions (14%). Compliance 
was good for each treatment, with 92% and 93% of the essential elements of the protocol being 
completed for VRE and EGT, respectively, and one infraction for each treatment arm across all sessions 
reviewed. Competence in delivering each element was also rated for these sessions, using a 7 point 
scale (1- very poor to 7-excellent). The competence ratings also were good, with a mean quality rating of 
6.1 for VRE and 5.4 for EGT. 
2.3.4 Long-term Follow-up Procedures 
A brochure was sent to the last known addresses of eligible participants, requesting their 
participation and updated contact information (i.e., phone number, email address) if applicable. 
Additionally, we provided a “do not contact” postcard to eligible participants with instructions to 
return the post card if they did not wish to be contacted or have any further involvement in the study. 
Approximately three weeks after the brochures/postcards were mailed we attempted to contact eligible 
participants by phone and/or email to provide additional study information and schedule long term 
follow-up in-person assessment for those who agreed to participate.  
The long-term follow-up assessment took place at Georgia State University and included a 
structured clinical interview (SCID), a behavioral avoidance task (BAT), and a battery of self-report 
questionnaires. Clinical interviews were conducted by advanced doctoral students in clinical 
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psychology; assessors were aware that participants had completed treatment but were blind to 
treatment condition. All long-term follow-up assessments were videotaped, and a randomly selected 
subset (N=5) were reviewed by the SCID trained assessment team, which included a licensed 
psychologist, to calculate the inter-rater reliability (100% agreement for primary diagnosis, with one 
disagreement on severity). Participants who completed the BAT were asked to deliver a speech to an 
audience consisting of 3 to 5 research staff; audience members were blind to treatment condition. 
Those who were unable to complete the in-person, follow-up assessment had the opportunity to 
complete questionnaires by mail. Participants who completed the in-person follow-up assessment 
received $50.00 compensation, while those who completed the questionnaires by mail received 
$25.00 as compensation for their time.   
2.3.5 Participants – Long-term Follow-up Completers 
Participants who previously received and completed either virtual reality exposure treatment 
(VRE) or exposure group treatment (EGT), in either of the two parent studies, were eligible for the 
current long-term follow-up study. Of the 75 eligible participants, twenty could not be contacted (e.g., 
number disconnected, did not return calls), five declined participation, seventeen agreed to take part in 
the study but never did so (e.g., no showed for assessment, did not return measures, did not return calls 
to schedule). The long-term follow-up assessment occurred on average 5.5 years after the completion of 
treatment, with the duration of follow-up ranging from 2.5 years to 6.5 years.   Long-term follow-up 
completers (N = 34) included individuals with a primary, pre-treatment diagnosis of either generalized (n 
= 17; 50%) or non-generalized social phobia (n = 17; 50%) who had previously completed either virtual 
reality exposure treatment (VRE; n = 18) or exposure group treatment (EGT; n = 16). The sample of long-
term follow-up completers was predominately female (67%); participants ranged in age from 20 to 69, 
with an average age of 40 (SD = 12.82).  The self-reported ethnic distribution of long-term follow-up 
completers was as follows:  “Caucasian” (n = 18; 53%), “African-American” (n = 10; 29%), “Latino” (n = 2; 
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6%), “Asian American” (n = 2; 6%), and “Other” (n = 2; 6%). Participants were generally well-educated, 
with 76% attaining an undergraduate degree or higher. A large portion (38%) of long-term follow-up 
completers reported an average annual income of $50,000 or more. Lastly, 44% reported their 
relationship status as married. 
2.3.6 Long-term Follow-up Measures 
Personal Report of Confidence as a Speaker (PRCS; Paul, 1966): The PRCS is a 30-item self-report 
questionnaire that measures public speaking confidence across three dimensions: before, during, and 
after delivering a speech (Appendix A). Items are presented in true-false format and are designed to 
measure participant’s feelings about their most recent speech. Summary scores range from 0 to 30 with 
higher scores indicating more public speaking discomfort. The PRCS has demonstrated good internal 
consistency α = .91 (Klorman, Weerts, Hastings, Melamed, & Lang, 1974), adequate validity (Lombardo, 
1988), and sensitivity to clinical change (Schutters, van Megen, and Westenberg, 2005) for individuals 
with social phobia. Internal consistencies for the treatment outcome study were as follows: poor for 
pretreatment (α = 0.42), good for midtreatment (α = 0.83), good for posttreatment (α = 0.87), good for 
3-month follow up (α = 0.88), and good for 12-month follow up (α = 0.87). Because the PRCS focuses on 
the measurement of public speaking fears (a primary target of both treatment interventions in the 
current study) and has demonstrated good psychometric properties it was used as a primary outcome 
measure at long-term follow-up. 
Fear of Negative Evaluation - Brief (BFNE; Leary, 1983): The BFNE is a widely used 12 item self-
report questionnaire that measures the degree to which individuals fear being negatively evaluated by 
others across a number of social settings, including public speaking (Appendix B). Ratings are based on 
responses to items such as, “I often worry that I will say or do wrong things.” Items are rated on a 5-
point scale ranging from 1 (not at all characteristic of me) to 5 (extremely characteristic of me). Scores 
range from 12 to 60 with higher scores representing increased evaluative concerns. The BFNE is 
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reported to have excellent internal consistency (α = .97) as well as test-retest reliability (r = .94) (Collins, 
Westra, Dozois, & Stewart, 2005). Internal consistencies for the treatment outcome study were as 
follows: good for pretreatment (α = 0.89), good for midtreatment (α = 0.90), good for posttreatment (α 
= 0.87), good for 3-month follow up (α = 0.91), and good for 12-month follow up (α = 0.89). Previous 
findings have indicated that the BFNE is sensitive to therapeutic changes among individuals who 
underwent CBT for social phobia (Collins, et al., 2005; Weeks et al., 2005).  
Liebowitz Social Anxiety Scale– Self Report Version (LSAS-SR; Liebowitz, 1987): The LSAS-SR is a 
24 item self report instrument assessing of fear and avoidance across a variety of social interactions and 
performance situations (Appendix C). Participants use a likert-type scale to provide ratings of fear (0 = 
none, 1 = mild, 2 = moderate, 3 = severe) and avoidance (0 = never, 1 = occasionally, 2 = often, 3 = 
usually) for each item. The measure has demonstrated high internal consistency among socially anxious 
individuals (α = .95) as well as and among individuals without an Axis I disorder (α = .94), appears to 
have strong convergent and discriminant validity (Fresco et al., 2001), and has demonstrated sensitivity 
to change (Heimberg et al., 1999).  As suggested in the Consensus Statement on Social Anxiety Disorder 
(Ballenger et al., 1998) the LSAS-SR will be used to operationalize treatment remission in the current 
study; more specifically, previous research (Menin, Fresco, Heimberg, et al., 2002) has indicated that the 
best sensitivity/specificity to identify an asymptomatic state was an LSAS-SR score of <30 and therefore 
this criteria will be used to qualify treatment remission in the current study. 
Long term follow-up Questionnaire (LTFQ): The LTFQ was developed specifically for the current 
study. It includes a variety of qualitative and quantitative self-report questions that are designed to 
provide a comprehensive assessment of long-term follow-up experiences (Appendix D).  Of particular 
importance to the current study, the LTFQ was used to assess whether participants had sought 
additional treatment for social phobia over the course of the long-term follow-up period, and if so what 
kind of treatment they had sought. 
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Patient Global Impression of Improvement (PGI-I; Guy, 1976): The PGI-I was adapted from the 
Clinician Global Impression of Improvement scale (CGI-I; Guy, 1976) and is a single item rate of change 
measure based on self-report responses to the following question, “compared to how I felt before 
beginning  this study, I now am.” Ratings are based on a seven point scale ranging from 1 (very much 
improved) to 7 (very much worse). Global improvement ratings are commonly used in the SP literature 
(Carlbring et al., 2009; Hedman et al., 2011) as a measure of treatment response, defined as a clinically 
significant reduction in symptoms (Ballenger et al., 1998), and the PGI-I will be used for such purposes in 
the current study. Participants who rate themselves as either very much improved or much improved on 
the PGI-I will be classified as treatment responders. 
Structured Clinical Interview for the DSM-IV (SCID; First, Gibbon, Spitzer, & Williams, 2002): The 
SCID is a structured diagnostic clinical interview used to assess psychological disorders based upon the 
criteria of the DSM-IV. It is widely used across research and clinical settings and is often regarded as the 
“gold standard” instrument in the assessment and diagnoses of Axis I disorders (Kessler et al., 2006; 
Shear et al., 2000). The SCID is well validated and it has demonstrated moderate to high inter-rater 
reliability (Riskind, Beck, Berchick, Brown, & Steer, 1987; Williams et al., 1992) in the diagnoses of Axis I 
disorders including assessments of social phobia (Antony, Orsillo, & Roemer, 2001) The anxiety, mood, 
and substance disorder modules were administered at the pre-treatment to assess inclusion and 
exclusion criteria and co-morbidity of some Axis I disorders. The anxiety module of the SCID was 
administered at long-term follow-up assessment to assess the presence/absence of current social 
phobia.  
Long-term Follow-up Medication Interview: a retrospective assessment of medication use that 
was designed specifically for the current study; included questions related to type, indication, dosage, 
and duration of all medications that were used, amongst our sample of long-term follow-up completers, 
both during and after treatment (Appendix E).   
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Behavioral Avoidance Test (BAT): The BAT was based on a standardized speech assessment 
protocol (Beidel, Turner, & Jacob, 1989) and involves the delivery of an impromptu speech. Participants 
were first given an index card with 5 randomly selected topics. Examples of the topics included capital 
punishment, abortion, corporal punishment in schools, same sex marriages, and organ donation. After 
receiving the index card, participants received three minutes to choose up to three topics and prepare 
notes for the speech. Participants were asked to try to speak for ten minutes on up to three topics. After 
completing the BAT, participants rated how well they performed (0-10) and how anxious they felt (0-10), 
with higher numbers indicating better performance and higher anxiety (Appendix F). Audience members 
included members of the research team that were not involved with treatment; prior to the entering the 
room to view the speech, audience members were made aware of BAT procedures (e.g., how topics 
were assigned, length of participant preparation time for speech), instructed to maintain a neutral 
stance throughout the speech, and afterwards independently rate (Appendix G) each speaker in regards 
to their performance and anxiety. BAT audience members were blind to treatment condition. The BAT 
was administered at pre-treatment, post-treatment, and long-term follow-up. However, audience 
members were only present at the post and long-term follow-up speeches. 
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 Fulfilled Inclusion Criteria  
Randomized to Treatment 
 (n = 97) 
Allocated to EGT (n = 40) 
• Dropped EGT (14) 
o Prior to Tx (5) 
o After Beginning Tx (9) 
Excluded (n = 59) 
• Not meeting inclusion criteria, excluded 
at pre-tx assessment (18) 
• Did not attend pre-tx assessment (41) 
Completed EGT Tx 
(n =26) 
Allocated to WL (n = 29) 
• Dropped WL (4) 
 
Allocated to VRE (n = 29) 
• Dropped VRE (4) 
o Prior to Tx (0) 
o After Beginning Tx (4) 
Completed WL 
(n =25) 
Completed VRE 
(n =25) 
A 
L 
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T 
X 
Dropped after WL (3) 
Randomized to EGT (n =11) 
• Dropped EGT (3) 
o Prior to Tx (2) 
o After beginning Tx (1) 
Randomized to VRE (n = 11) 
• Dropped VRE (4) 
o Prior to Tx (1) 
o After beginning Tx (3) 
Total VRE Completers  
 (n = 32) 
Completed Phone Screen (n = 191) Eligible for Pre-tx Assessment 
(n = 157) 
Total EGT Completers  
 (n = 34) 
P 
O 
S
T 
 
T 
X 
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L 
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T 
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O 
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Figure 1. CONSORT participant flow chart for Study 1 (FOPS II) 
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 Fulfilled Inclusion Criteria  
Assigned to Treatment & 
Completed Dot Probe 
 (n = 14) 
• Did not attend pre-tx 
assessment (7) 
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T 
Assigned to VRE (n =14) 
• Dropped VRE (4) 
o Prior to Tx (2) 
o After beginning Tx (2) 
Completed Phone Screen 
(n = 41) 
 Eligible for Pre-tx Assessment  
(n = 26) 
Excluded (n = 5) 
• Not meeting inclusion 
criteria, excluded at pre-tx 
assessment (5) 
 Attended Pre-tx assessment 
 (n = 19) 
Total VRE Completers  
(n =10)  
Figure 2. TREND participant flow chart for Study 2 (FMRI) 
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3     RESULTS 
3.1 Preliminary Analyses 
Prior to conducting the primary analyses all variables were screened for errors, outliers (defined 
as scores greater than three standard deviations from the mean), and missing values. No outliers were 
identified for the primary dependent variables. Descriptive statistics for the primary variables of interest 
at each assessment point are presented in Table 1.  Chi-square analyses indicated that there were no 
significant demographic differences between long-term follow-up completers and non-completers. A 
series of t-tests revealed no significant differences in pretreatment symptoms (PRCS, BFNE, LSAS-F, 
LSAS-A) between long-term follow-up completers and non-completers (see Tables 2 and 3). Moreover, 
long-term follow-up completers did not differ from non-completers with regards to post-treatment 
social phobia symptoms (see Tables 4 and 5). For the primary analyses a series of 3 X 2 (Time X 
Treatment Condition) repeated measures ANOVAs were conducted to test the following hypotheses: (1) 
that ratings of social phobia would be significantly lower at long-term follow-up in comparison to pre-
treatment ratings and (2) that post-treatment gains would be maintained at long-term follow-up.  
 
3.2 Self-Report Measures of Social Phobia  
Results revealed a significant main effect of time across each of the primary self-report 
measures including the LSAS-Avoidance, F (2, 60) = 19.70, p <.001, partial ƞ2 = .40, the LSAS-Fear, F (2, 
60) = 20.75, p <.001, partial ƞ2 = .41, the BFNE, F (2, 58) = 8.18, p <.01, partial ƞ2 = .22, and the PRCS, F 
(2, 60) = 37.85, p <.001, partial ƞ2 = .56. Post hoc analyses using Bonferroni-corrected pairwise 
comparisons revealed that social anxiety ratings were significantly lower at post-treatment, in 
comparison to pre-treatment ratings, across each of the primary self-report measures: LSAS-Avoidance 
(M difference = -6.83, p < .001), LSAS-Fear (M difference = -5.98, p < .001), BFNE (M difference = -5.35, p 
= .003), PRCS (M difference = -11.73, p < .001). As hypothesized, long-term follow-up ratings of social 
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phobia were also significantly lower, in comparison to pre-treatment ratings, for all self-report 
measures: LSAS-Avoidance (M difference = -8.78, p < .001), LSAS-Fear (M difference = -8.47, p < .001), 
BFNE (M difference = -5.69, p = .005), PRCS (M difference = -9.89, p < .001). No significant differences 
were observed between post-treatment and long-term follow-up scores: LSAS-Avoidance (M difference 
= 1.98, p = .52), LSAS-Fear (M difference = 2.49, p = .07), BFNE (M difference = .34, p = 1.00), PRCS (M 
difference = -1.84, p = .84).  
With regards to treatment group, no significant main effects were observed on the BFNE, F (1, 
29) = .04, p = .85, partial ƞ2 = .00; the LSAS-Fear, F (1, 30) = .53, p = .47, partial ƞ2 = .02; or the LSAS-
Avoidance, F (1, 30) = 3.54, p = .07, partial ƞ2 = .16. Moreover, there was no Time X Treatment Group 
interaction on the BFNE, F (2, 58) = 1.33, p = .27, partial ƞ2 = .04, the LSAS-Fear, F (2, 60) = .56, p = .54, 
partial ƞ2 = .02, or the LSAS-Avoidance, F (2, 60) = 1.32, p = .27, partial ƞ2 = .04. However, there was a 
significant main effect of treatment group on the PRCS, F (1, 30) = 4.82, p =.036, partial ƞ2 = .14. 
Moreover, the main effects of time and treatment group on the PRCS were qualified by a significant 
Time X Treatment Group interaction, F (2, 60) = 5.39, p = .007, partial ƞ2 = .15. The Time X Treatment 
group interaction on the PRCS was further probed by testing for the simple main effects of treatment 
group at each time point; results revealed that EGT participants reported significantly lower PRCS 
scores, in comparison to VRE participants, at post-treatment, F (1, 33) = 16.77, p < .001, partial ƞ2 = .34, 
but not at pre-treatment, F (1, 33) = 2.91, p = .09, partial ƞ2 = .08, or at long-term follow-up, F (1, 31) = 
1.60, p = .22, partial ƞ2 = .05.   
 
3.3 Behavioral Ratings 
3.3.1 Behavioral Avoidance Task – Participant Ratings  
 Next, a 3 X 2 ANOVA (Time X Condition) was used to analyze participant ratings of 
anxiety and performance on the behavioral avoidance task (speech). For participant ratings of anxiety, 
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there was a significant main effect of time, F (2, 36) = 4.22, p = .023, partial ƞ2 = .19, but not for 
treatment group, F (1, 18) = .18, p = .68, partial ƞ2 = .01, or for the Time X Group interaction, F (2, 36) = 
1.39, p = .26, partial ƞ2 = .07. Post hoc pairwise comparisons showed that participants’ anxiety ratings 
were significantly lower at long-term follow-up in comparison to pre-treatment (M difference = -1.54, p 
< .05). No significant differences were observed for between pre-treatment and post-treatment (M 
difference = 1.44, p = .07) or post-treatment and long-term follow-up (M difference = .104, p = 1.00) for 
participants’ rating of anxiety. Similarly, for participants’ rating of performance, there was a significant 
main effect of time, F (2, 34) = 16.76, p <.001, partial ƞ2 = .49, but not for treatment group, F (1, 17) = 
.03, p = .88, partial ƞ2 = .00, or for the Time X Group interaction, F (2, 34) = .87, p = .43, partial ƞ2 = .05. 
Post hoc pairwise comparisons showed that participants rated their speech performance as significantly 
better at post-treatment (M difference = 3.44, p < .001) and at long-term follow-up (M difference = 1.84, 
p = .05) in comparison to pre-treatment. Of note, there was also a significant difference between long-
term follow-up and post-treatment participant rated performance scores (M difference = 1.60, p < .05) 
with participants rating their performance better at post-treatment than at long-term follow-up. 
3.3.2 Behavioral Avoidance Task – Audience Ratings 
 The pre-treatment behavioral avoidance task did not include an audience therefore the 
following results are based on comparisons of post-treatment and long-term follow-up audience ratings. 
Results indicated that audience members rated participants similarly, in terms of anxiety and 
performance, at post-treatment and long-term follow-up. Specifically, we did not observe a main effect 
of time for audience-rated performance, F (1, 16) = .03, p = .86, partial ƞ2 = .86 or for audience-rated 
anxiety, F (1, 16) = 9.74, p = .07, partial ƞ2 = .19. Moreover, the effect of treatment group was not 
significant for audience-rated performance, F (1, 16) = .10, p = .76, partial ƞ2 = .00, or for audience-rated 
anxiety, F (1, 16) = .02, p = .88, partial ƞ2 = .01. Finally, the Time X Treatment Group interaction was not 
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significant for audience-rated performance, F (1, 16) = 2.05, p = .17, partial ƞ2 = .11, or for audience-
rated anxiety, F (1, 16) = 1.82, p = .19, partial ƞ2 = .10. 
Before moving on it is important to note that the majority of long-term follow-up participants 
completed the BAT (27/34; 79%); in fact, of the twenty-seven participants who were able to attend the 
long-term follow-up assessment in person all but one agreed to give a speech (96%). In comparison, 
sixty-eight percent of long-term follow-up participants (23/34) completed the post-treatment BAT.   
 
3.4 Additional Treatment during Follow-up 
Self-reported responses on the Long-term Follow-up Questionnaire (LTFQ) indicated that none 
the long-term follow-up completers had sought additional treatment (therapy) for social phobia during 
the follow-up period. However, one participant indicated that they had started medication (propranolol) 
for social phobia during follow-up on the Long-term Follow-up Medication Interview.  
 
3.5 Treatment Response/Remission 
In addition to examining long-term treatment outcomes via comparisons of group means, we 
analyzed each participant individually using the treatment response and remission suggestions set forth 
by the Consensus Statement on Social Anxiety (Ballenger et al., 1998). As previously discussed, treatment 
response was operationalized according to global improvement ratings on the PGI-I; participants who 
rated themselves as either very much improved or much improved were considered to have responded 
to treatment; accordingly, 65% (n = 22) of participants were characterized as treatment responders at 
long-term follow-up with 41% (n = 14) rating themselves as very much improved and 24% (n = 8) rating 
themselves as much improved. In comparison, 76% (n = 26) of long-term follow-up completers were 
characterized as treatment responders at post-treatment with 50% (n = 17) rating themselves as very 
much improved and 26% (n = 9) rating themselves as much improved. A chi-square analysis indicated no 
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significant difference in the number of treatment responders at post-treatment versus long-term follow-
up χ2 (1) = 2.09, p = 0.15. 
Treatment remission was operationalized via participant self-report ratings on the LSAS-SR using 
a clinical cutoff score of < 30. Based on LSAS-SR ratings, 47% (n = 16) of participants were considered to 
be in remission at long-term follow-up. In comparison, 32% (n = 11) of long-term follow-up completers 
were considered to be in remission at post-treatment (as measured by their LSAS-SR ratings). A chi-
square analysis indicated that the number of long-term follow-up completers in remission at long-term 
follow-up was significantly higher than the number in remission at post-treatment χ2 (1) = 7.34, p = .007 
Treatment remission was also assessed according to DSM-IV diagnostic criteria (clinician ratings on the 
SCID); accordingly, 56% (n = 19) participants no longer meet diagnostic criteria for social phobia at long-
term follow-up. Of the participants who still met criteria for SP at long term follow-up nine were 
diagnosed with generalized SP while two were considered to meet criteria for non-generalized SP. 
Among those who retained a social phobia diagnosis at follow-up, severity ratings ranged from mild (n = 
5), to moderate (n = 5), to severe (n = 1).   
 
3.6 Long-term Outcomes of Concurrent Medication 
We were unable to examine the impact of medication use on long-term follow-up due to a lack 
of power. Of the thirty-four long-term follow-up completers, only three reported taking medication for 
social phobia during treatment and of those three only one had discontinued medication during the 
follow-up period. According to SCID ratings, the participant that discontinued social phobia medication 
during follow-up continued to meet diagnostic criteria for severe, non-generalized social phobia at long-
term follow-up.  Moreover, the participant’s long-term follow-up LSAS-SR score (>30) corroborated 
his/her not being in remission at long-term follow-up. Additional evidence of the participant’s lack of 
treatment response was confirmed by a long-term follow-up global improvement rating of “minimally 
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improved.” Self-report ratings of social phobia and behavioral ratings of anxiety/performance for the 
participant that discontinued medication during follow-up are presented in Table 8. 
To summarize, the findings indicate that participants showed significant improvements at post-
treatment which were maintained over the course of the long-term follow-up period, as evidenced by 
non-significant differences in self-reported and behavioral ratings of social anxiety between the post- 
and long-term follow-up assessments.  
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Table 1. Descriptives for primary outcomes at pre, post, and long-term follow-up 
 
Note. Values in parentheses are standard deviations. BFNE = Fear of Negative Evaluation, Brief Form. PRCS = 
Personal Report of Confidence as a Speaker. LSAS-Fear = Liebowitz Social Anxiety Scale, Fear subscale. LSAS-
Avoidance = Liebowitz Social Anxiety Scale, Avoidance Subscale.  VRE = Virtual Reality Exposure.  EGT = Exposure 
Group Therapy.  
 
Variable 
 
Pre-treatment 
 
Post-treatment 
 
Long-Term Follow-up 
 
N 
 
Self Report Measures  
    
     
     PRCS     
VRE 24.06 (3.27) 17.06 (6.06) 17.00 (9.77) 17 
EGT 25.87 (2.79) 9.40  (5.83) 13.13 (7.09) 15 
Total 24.91 (3.15) 13.47 (7.03) 15.19 (8.71) 32 
    BFNE     
VRE 38.76 (10.53) 35.71 (8.31) 35.24 (5.91) 17 
EGT 42.21 (8.29) 34.57 (5.88) 34.36 (10.93) 14 
Total 40.32 (9.59) 35.19 (7.22) 34.84 (8.40) 31 
    LSAS-Fear     
VRE 24.53 (9.37) 19.96 (7.82) 17.00 (8.85) 17 
EGT 28.27 (10.39) 20.88 (9.57) 18.87 (10.98) 15 
Total 26.28 (9.88) 20.39 (8.55) 17.88 (9.79) 32 
    LSAS-Avoidance     
VRE 20.12 (8.49) 15.66 (7.74) 12.76 (8.24) 17 
EGT 27.87 (9.45) 18.67 (10.58) 17.67 (10.59) 15 
Total 23.75 (9.65) 17.07 (9.15) 15.06 (9.58) 32 
 
BAT 
    
     
    Speaker Anxiety      
VRE 6.42 (2.75) 5.67 (1.56) 5.83 (3.00) 12 
EGT 7.13 (2.29) 5.00 (2.45) 4.63 (2.67) 8 
Total 6.70 (2.54) 5.40 (1.93) 5.35 (2.87) 20 
    Speaker Performance       
VRE 2.92 (2.61) 6.50 (1.17) 4.17 (2.04) 12 
EGT 2.71 (2.14) 6.00 (1.53) 5.14 (.89) 7 
Total 2.84 (2.39) 6.32 (1.29) 4.53 (1.74) 19 
    Audience Anxiety     
VRE -- 4.33 (1.41) 4.65 (2.05) 10 
EGT -- 3.50 (1.81) 5.27 (1.99) 8 
Total -- 3.96 (1.61) 4.92 (1.99) 18 
    Audience Performance      
VRE -- 6.26 (1.38) 7.25 (1.64) 10 
EGT -- 6.96 (2.43) 6.19 (1.62) 8 
Total -- 6.57 (1.89) 6.78 (1.67) 18 
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Table 2. Comparison of pre-treatment scores for LTF completers versus LTF non-completers 
 
  
Completers 
  
Non-Completers 
  
 
Variable 
 
n 
 
M (SD) 
  
n 
 
M (SD) 
 
t (df) 
 
P 
        
PRCS 33 24.85 (3.11)  40 25.30 (2.55) .68 (71) .49 
 
BFNE 33 40.24 (9.30)  42 44.00 (8.75) 1.80 (73) 
 
.08 
LSAS-Fear 
 
33 25.88 (9.99)  42 28.55 (12.23) 1.02 (73) .31 
LSAS-Avoidance 33 23.39 (9.71)  42 23.98 (11.50) .23 (73) .82 
 
Note. BFNE = Fear of Negative Evaluation, Brief Form. PRCS = Personal Report of Confidence as a Speaker. LSAS-
Fear = Liebowitz Social Anxiety Scale, Fear subscale. LSAS-Avoidance = Liebowitz Social Anxiety Scale, Avoidance 
Subscale.   
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Table 3. Comparison of mean pre-treatment scores for LTF completers versus LTF non-completers within 
treatment conditions 
 
                            
                     Virtual Reality Exposure ______  
               
                   Exposure Group Therapy   ________ 
 
Variable 
 
Completers 
(n=18) 
Non- 
Completers 
(n=24) 
 
t 
 (df) 
 
p 
  
 
Completers 
(n=15) 
Non-
Completers 
(n=18) 
 
t  
(df) 
 
p 
         
PRCS 24.00 
(3.18) 
24.92 
(2.41) 
1.06 
(40) 
.29 25.87  
(2.80) 
25.88  
(2.73) 
.01 
 (29)  
.99 
         
BFNE 38.89 
(10.23) 
42.71 
(9.81) 
1.22 
(40) 
.23 41.87  
(8.10) 
45.72  
(6.98) 
1.47 
(31)  
.15 
         
LSAS- 
Fear 
23.89 
(9.49) 
26.38 
(12.22) 
.72 
(40) 
.48 28.27 
 (10.39) 
31.44  
(11.95) 
.81  
(31) 
.43 
         
LSAS-
Avoidance 
19.67 
(8.46) 
21.62 
(10.07) 
.67 
(40) 
 
.51 27.87 
(9.45) 
27.11  
(12.79) 
 
-.19 
(31) 
.85 
Note. BFNE = Fear of Negative Evaluation, Brief Form. PRCS = Personal Report of Confidence as a 
Speaker. LSAS-Fear = Liebowitz Social Anxiety Scale, Fear subscale. LSAS-Avoidance = Liebowitz Social 
Anxiety Scale, Avoidance Subscale.   
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Table 4. Comparison of post-treatment scores for LTF completers versus LTF non-completers 
 
  
Completers 
  
Non-Completers 
  
 
Variable 
 
n 
 
M (SD) 
  
n 
 
M (SD) 
 
t (df) 
 
P 
        
PRCS 32 13.72 (7.26)  40 13.65 (7.35) - .04 (70) .97 
 
BFNE 31 35.71 (6.73)  40 36.55 (8.73) .44 (69) 
 
.66 
LSAS-Fear 
 
32 20.64 (8.26)  39 21.08 (13.50) .16 (69) .87 
LSAS-Avoidance 32 17.51 (8.94)  39 15.52 (13.26) - .72 (69) .47 
 
Note. BFNE = Fear of Negative Evaluation, Brief Form. PRCS = Personal Report of Confidence as a 
Speaker. LSAS-Fear = Liebowitz Social Anxiety Scale, Fear subscale. LSAS-Avoidance = Liebowitz Social 
Anxiety Scale, Avoidance Subscale.   
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Table 5. Comparison of mean post-treatment scores for LTF completers versus LTF non-completers within 
treatment conditions 
 
Note. BFNE = Fear of Negative Evaluation, Brief Form. PRCS = Personal Report of Confidence as a 
Speaker. LSAS-Fear = Liebowitz Social Anxiety Scale, Fear subscale. LSAS-Avoidance = Liebowitz Social 
Anxiety Scale, Avoidance Subscale.   
 
 
 
 
 
 
 
 
 
                               
                  Virtual Reality Exposure ________ 
               
                    Exposure Group Therapy  _________ 
 
Variable 
 
Completers 
(n=17) 
Non-
Completers 
(n=23) 
 
t 
(df) 
  
 p 
 
Completers 
(n=15) 
Non-
Completers 
(n=16) 
 
t  
(df) 
 
p 
         
PRCS 17.53 
(6.28) 
15.26 
(7.83) 
- .98 
(38) 
 
.33 9.40 
(5.83) 
11.47 
(6.22) 
.97 
(30) 
.34 
BFNE 36.65 
(7.40) 
37.26 
(9.71) 
.22  
(38) 
.83 34.57 
(5.88) 
35.59 
(7.39) 
.42 
(29) 
.68 
         
LSAS-Fear 20.43 
(7.20) 
22.00 
(15.53) 
.39  
(38) 
.70 20.88 
(9.57) 
19.75 
(10.22) 
- .32 
(29) 
.75 
         
LSAS-
Avoidance 
19.67 
(8.46) 
21.62 
(10.07) 
.67  
(40) 
 
.51 18.67 
(10.58) 
13.46 
(8.60) 
 
-1.51 
(29) 
.14 
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Table 6. 3 X 2 (Time X Condition) ANOVA comparing self-report ratings at pre-treatment, post-treatment, and long-term follow-up 
 
  
 
                VRE_______   
  
 
             EGT_____ 
 
Main Effect 
      of Time___ 
 
Main Effect 
         of Tx___ 
 
 
     Interaction__ 
 
 
               Cohen’s d___________ 
 
 
Variable 
Pre Post LTF  Pre 
 
Post LTF F p F p F p Pre - 
Post 
 
Pre-  
LTF 
Post - 
LTF 
PRCS 24.06 
(3.23) 
17.06 
(6.06) 
17.00 
(9.77) 
 
 25.87 
(2.80) 
9.40 
(5.83) 
13.13 
(7.09) 
37.85 
  
<.001 4.82 <.05 5.39 <.01 2.10 1.48 0.22 
                 
BFNE 38.76 
(10.53) 
35.71 
(8.31) 
35.23 
(5.91) 
 
 42.21 
(8.29) 
34.57 
(5.88) 
34.36 
(10.93) 
8.18  <.01 .04 .848 1.33 .272 0.60 0.61 0.05 
                 
LSAS- 
Fear 
24.53 
(9.37) 
19.96 
(7.82) 
17.00 
(8.85) 
 
 28.27 
(10.35) 
20.88 
(9.57) 
18.87 
(10.98) 
20.75 <.001 .53 .471 .56 .540 0.64 0.85 0.27 
                 
LSAS- 
Avoidance 
20.12 
(8.50) 
 
15.66 
(7.74) 
12.76 
(8.24) 
 
 27.87 
(9.45) 
18.67 
(10.58) 
17.67 
(10.59) 
19.70 <.001 3.54 .070 1.32 .274 0.71 0.90 0.22 
Note. BFNE = Fear of Negative Evaluation, Brief Form. PRCS = Personal Report of Confidence as a Speaker. LSAS-Fear = Liebowitz Social Anxiety 
Scale, Fear subscale. LSAS-Avoidance = Liebowitz Social Anxiety Scale, Avoidance Subscale.  Values in parenthesis are standard deviations.  
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Table 7. 3 X 2 (Time X Condition) ANOVA comparing BAT ratings at pre-treatment, post-treatment, and long-term follow-up 
 
 
 
 
            
                 VRE_________   
  
            
               EGT  ______ 
 
Main Effect 
        of Time___ 
 
Main Effect 
         of Tx___ 
 
     
 Interaction__ 
Coh  
                                        Cohen’s d           ______ 
 
Variable 
Pre Post LTF  Pre 
 
Post LTF F p F p F p Pre - Post 
 
Pre - LTF Post - LTF 
                 
BAT Anxiety: 
Audience Rated 
-- 4.33 
(1.41) 
4.65 
(2.05) 
 -- 3.50 
(1.81) 
5.27 
(1.99) 
3.80 .069 .02 .884 1.82 .196 -- -- 0.53 
                 
BAT Anxiety: 
Participant Rated 
6.42 
(2.75) 
5.67 
(1.56) 
5.83 
(3.00) 
 7.13 
(2.30) 
5.00 
(2.45) 
4.63 
(2.67) 
4.22 <.05 .18 .675 1.39 .263 0.58 0.50 0.02 
                 
BAT Performance: 
Audience Rated 
-- 6.26 
(1.38) 
7.25 
(1.64) 
 -- 6.96 
(2.43) 
6.19 
(1.62) 
.03 .857 .10 .755 2.05 .171 -- -- 0.12 
                 
BAT Performance: 
Participant Rated 
2.92 
(2.61) 
6.50 
(1.17) 
4.17 
(2.04) 
 2.71 
(2.14) 
6.00 
(1.53) 
5.14 
(.90) 
 
16.76 <.001 .03 .877 .87 .430 1.81 0.81 1.17 
Note. Audience ratings were not collected at pre-treatment. Values in parentheses are standard deviations. 
45 
 
 
4 DISCUSSION 
The current study sought to add to the literature by being one of the most methodologically 
sound long-term follow-ups of CBT for social phobia (SP) to date; being the first to examine long-term 
outcomes of virtual reality exposure therapy (VRE) in the treatment of SP; using a multimodal approach 
(self-report, clinician rated, and behavioral) to assess long-term treatment gains; and providing new 
insight about the long-term implications of psychotropic medication use during treatment for SP.   We 
were unable to examine our hypothesis that psychotropic medication use would attenuate long-term 
treatment gains due to a lack of power.  Specifically, only one participant who was taking medication for 
SP during treatment had discontinued their medication at long-term follow-up. We were, however, able 
to evaluate the extent to which people with social phobia who received one of two forms of short-term 
CBT fared in the long term.  Results showed that participants demonstrated significant improvements 
several years (M = 5.5 years) after completing treatment, relative to pre-treatment, with no difference 
between treatment groups on all but one self-report measure (PRCS). Gains made during treatment 
were maintained during the follow-up period with no significant differences on any measure between 
the post-treatment assessment and the long-term follow-up assessment, with the exception of 
participants’ BAT performance ratings, which were better at LTF than post-treatment and treatment 
remission rates . The maintenance of post-treatment gains at long-term follow-up was further 
corroborated by the small effects that were observed for all self-report measures of social phobia 
symptomatology (d = .05    .27) as well as self-reported anxiety on the BAT (d = .02). Audience ratings 
on the BAT ranged from small (d = .12; performance) to medium (d = .53; anxiety).   
Our primary finding that EGT and VRE treatment gains are well-maintained several years after 
the completion of treatment is commensurate with previous research on the maintenance of treatment 
gains following a variety of forms of CBT for social phobia 2-10 years following treatment, including  
cognitive behavioral group therapy (Heimberg et al., 1993), intensive group cognitive therapy/individual 
 cognitive therapy (Mortberg et al., 2011), resource-oriented cognitive-behavior therapy/traditional 
cognitive therapy (Willutzki, Teismann, & Schulte, 2012), internet delivered CBT (Carlbring et al., 2009; 
Hedman et al., 2011), social effectiveness therapy (Turner et al., 1995), a group behavioral intervention 
targeting social/interpersonal deficits (Stravynski et al., 2000) , and an “exposure-based homework” 
protocol  (Fava et al., 2001). In addition to maintaining post treatment gains, internet delivered CBT, 
social effectiveness therapy, and resource oriented/CBT treatment completers are reported to have 
continued to improve significantly from post-treatment to long-term follow-up (Carlbring et al., 2009; 
Hedman et al., 2011; Turner et al., 1995; Willutski et al., 2012).  
 
4.1 Strengths and Limitations 
The current study is the first to evaluate the long term utility of VRE treatment in a clinical 
sample of individuals with social phobia.  Recall that  previous studies have yielded support for the 
short-term efficacy of VRE in the treatment of a variety of anxiety disorders including social phobia 
(Anderson et al., 2005; Klinger et al., 2005; Wallach et al., 2009)  but very little is known about the 
extent to which VRE treatment gains are maintained over the long haul. Safir and colleagues (2012) 
conducted the only long-term follow-up study of a randomized clinical trial testing VRE for social fears—
findings from this study, based on participants’ self-report ratings, revealed that socially fearful 
individuals generally maintained their VRE post-treatment gains at one year follow-up (Safir et al., 2012). 
Consistent with the findings reported by Safir et al. (2012), results from the current study revealed that 
VRE treatment gains were maintained at long-term follow-up  across all measures (self-report, clinician, 
behavioral). Furthermore, the current study offers several methodological advantages including a much 
longer follow-up period (1 year versus up to 6.5 years), a clinical sample of individuals with social 
phobia, and an assessment of behavior. Though further studies and replication are needed, the current 
findings provide preliminary support for the long-term maintenance of VRE gains several years after the 
 completion of treatment—this is particularly important considering that VRE could potentially benefit 
those who do not respond to traditional, in-vivo exposure treatments for SP.  
Another important aspect of the current study is that our assessment included a behavioral 
avoidance task (BAT) – giving a speech. Only one previous long-term follow-up study of social phobia 
treatment included a BAT (Heimberg et al., 1993). Furthermore, the current study is the first to 
incorporate a BAT as a part of a long-term follow-up assessment of VRE.   Though rarely utilized in long-
term follow-up studies BATs are recommended as a part of evidence-based assessment for 
anxiety/phobias (Hood & Antony, 2012; Zlomke & Davis, 2008) and are considered to be extremely 
useful in the assessment of outcomes due to their high sensitivity to change (Craske et al., 1988; 
McGlynn, 1988). The behavioral data from the current study are promising; the vast majority (79%) of 
participants completed the speech task at the long-term follow-up.  Audience ratings of performance 
and anxiety indicated that participants maintained post-treatment gains at follow-up. Participants, 
however, reported that their performance was better at long-term follow-up than post-treatment, 
although their anxiety was no different at follow-up in comparison to post-treatment. In sum, behavioral 
data from the current study provide additional evidence to support the long-term utility of VRE and EGT 
in the treatment of social phobia.  
 One major challenge that limits the interpretation of data from long-term follow-up studies is 
receipt of additional treatment during the follow-up period (Chambless & Ollendick, 2001). An 
important strength of the current study is that all but one of our long-term follow-up participants denied 
seeking additional treatment between post-treatment and long-term follow-up—this is important 
because it increases our confidence about the internal validity of the current findings. In contrast, 
additional treatment during follow-up has been relatively common in previous long-term follow up 
studies for SP. For internet delivered CBT, rates of participants who report seeking some form of 
additional help after the completion of treatment range from 11% (at two year follow-up; Carlbring et 
 al., 2009) to 29% (at five year follow-up; Hedman et al., 2011). Approximately 20% of individuals 
reported seeking additional treatment after the completion of social effectiveness therapy (Turner et al, 
1995). Five out of eighteen participants in Heimberg et al.’s (1993) long-term follow-up of CBGT and EST 
reported seeking additional treatment. Finally, Mortberg and colleagues (2011) reported that 25% of 
participants had sought additional treatment after the completion of intensive cognitive therapy or 
intensive group cognitive therapy. Unfortunately, the reporting of additional treatment in long-term 
follow-up studies has generally been vague; most studies have not specified the type of additional 
treatment received or why additional treatment was sought (e.g. for SP or something else). 
Nevertheless, with the exception of one study (Carlbring et al., 2009), studies that reported on 
additional treatment conducted additional analyses which all confirmed that participants who sought 
additional treatment did not differ significantly from those that did not with regards to SP 
symptomatology at long-term follow-up (Hedman et al., 2011; Heimberg et al., 1993; Mortberg et al., 
2011).  
Attrition is an issue of common concern in follow-up studies in general, and the current study is 
no exception, with a response rate of 45% (N = 34). Of the 75 participants who were eligible to 
participate, 20 could not be contacted (e.g., number disconnected, did not return calls), another 17 
agreed to take part in the study but never did (e.g., no-showed for assessment, did not return measures, 
did not return calls to schedule), and 5 declined participation. The response rate for the current study is 
comparable to the rate (51%) observed by Heimberg and colleagues (1993) in the only other known in-
person, long-term follow-up assessment that included self-report, clinician rated, and behavioral 
outcome measures. Response rates for other long-term (2+ years after treatment) outcome studies vary 
widely: interpersonal-focused behavioral group treatment (N = 4; 100%), internet delivered CBT (N = 44; 
77%, Carlbring et al., 2009; N = 71; 89% Hedman et al., 2011) intensive cognitive therapy/intensive 
cognitive group therapy (N = 42; 78%), homework based exposure (N = 45; 64%), social effectiveness 
 therapy (N = 8; 62%), and resource oriented CBT (N = 27; 31%). Offering participants the option of 
completing self-report outcome measures online and/or conducting clinical interviews by phone rather 
than in-person seems to improve response rates  (e.g., Carlbring et al., 2009; Hedman et al., 2011; 
Mortberg et al., 2011; Willutski et al., 2012), but was not feasible for this study because of the use of a 
behavioral avoidance test.   
Systematic attrition (e.g., participant loss that is not random) can be particularly problematic 
because it threatens both the internal validity and the external validity of reported findings. For 
example, Heimberg et al. (1993) reported that their sample of long-term follow-up completers were not 
fully representative of the treated sample—completers presented to treatment with significantly fewer 
symptoms of social phobia than non-completers. In the case of Heimberg et al. (1993) selective attrition 
limited the extent to which the researchers could attribute the reported long-term gains to treatment 
(internal validity) as well as the extent to which their findings could be generalized to the population 
(external validity).   Selection bias is a related methodological short-coming evident in previous long-
term investigations of homework based exposure (Fava et al., 2001) and interpersonal-focused 
behavioral group treatment (Stravinsky et al., 2000) which excluded individuals who were not in 
remission at post-treatment. In light of the incidence of selection bias and systematic attrition in the 
long-term follow-up literature additional research is needed to solidify our understanding and 
confidence regarding the long-term efficacy of SP treatment interventions as a whole. Fortunately, our 
analyses of follow-up completers versus non-completers did not reveal significant pre-treatment or 
post-treatment differences in terms of symptom severity; thus, although attrition in the current study is 
notable these findings suggest that our sample of follow-up completers was representative of the 
treated sample and provide support for the validity of our findings.  
Before moving forward, it is important to discuss some additional external validity issues that 
are particularly relevant to the current study. First,  the inclusion criteria for the two parent studies 
 specified that fear of public speaking must be the primary social fear--some have argued that public 
speaking anxiety may be a specific subtype of social anxiety disorder with manifestations that are not 
necessarily consistent with generalized social anxiety (Blöte, Kint, Miers, & Westenberg, 2009). Also, the 
co-morbidity in the current sample (12%) is lower than what is typically found for individuals with social 
anxiety disorder, although it is comparable to comorbidity reported in other research utilizing internet-
based or virtual reality for public speaking fears (7% - 12.5%; Andersson et al., 2006; Botella et al., 2008). 
Finally, although the ethnic/racial diversity in the current sample represents the diverse community in 
which the study was conducted, such populations are underrepresented in treatment efficacy research 
(Whaley & Davis, 2007), including virtual reality exposure therapy.   
 
4.2 Future Directions 
While results from the current study and previous studies offer consistent support for the long-
term maintenance of CBT in the treatment of social phobia, much of the current characterized by 
statistically significant changes based on clinician and self-reported ratings of social phobia-- the extent 
to which these statistically significant changes amount to clinically significant changes is not yet clear. In 
an effort to further elucidate the relation between statistically significant and clinically significant 
change, future long-term follow-up studies should regularly incorporate multimodal assessment 
techniques including self-report, clinician rated, physiological, and behavioral measures of social anxiety. 
Previous researchers have suggested that behavioral assessments, like the BAT used in the current 
study, are an important part of treatment outcome research because they provide an assessment of 
clinically significant change in “real world” functioning (Kazdin, 1999; Norton & Hope, 2001; Bunnell, 
Beidel, & Mesa, 2013). Furthermore, behavioral assessments are thought to offer unique clinical insight 
by providing clinicians with the opportunity to observe and assess avoidance and/or safety behaviors as 
well as social skills and performance. 
 Another important area of future research will be to identify and examine predictors of long-
term treatment success for SP. One study to date has reported on predictors of long-term outcome; 
findings from Fava and colleagues (2001) identified the following predictors of relapse 1) the presence 
of a comorbid personality disorder, 2) residual symptoms of SP after the completion of treatment, and 
3) failure to completely withdraw from benzodiazepines during exposure treatment. The finding that 
failure to withdrawal from benzodiazepines during exposure treatment is in line with our hypothesis 
that medication use during CBT for SP may attenuate long-term treatment gains and further highlights 
the need for additional research in this area.  
 
4.3 Conclusions 
In summary, the current study examined the long-term efficacy of cognitive behavioral therapy 
for social phobia. Results supported the long-term maintenance of gains made following individual (VRE) 
and group (EGT) treatment and are consistent with previous literature which has generally supported 
the long-term efficacy of CBT in the treatment of social phobia. Primary contributions of the current 
study include: being the first to examine long-term outcomes of VRE in a clinical sample of individuals 
with social phobia and by incorporating a multimodal assessment approach, including a behavioral 
avoidance task, at long-term follow-up which has only been done once before (Heimberg et al., 1993). 
To conclude, the current findings are important because they suggest that exposure in the virtual world 
or in vivo may be followed by long-lasting behavioral changes in the real world.  
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 APPENDICES 
Appendix A.  
PRCS 
 
This instrument is composed of 30 items regarding your feelings of confidence as a speaker. Try to 
decide whether “true” or “false” most represents your feelings associated with your most recent 
speech. Then write “T” or “F” next to each question to indicate your answer. Work quickly and don’t 
spend much time on any one question. We want your first impression on this questionnaire. 
 
1. I look forward to an opportunity to speak in public. _____ 
 
2. My hands tremble when I try to handle objects on the platform. ____ 
 
3. I am in constant fear of forgetting my speech. _____ 
 
4. Audiences seem friendly when I address them. _____ 
 
5. While preparing a speech I am in a constant state of anxiety. _____ 
 
6. At the conclusion of a speech I feel that I have had a pleasant experience. ______ 
 
7. I dislike to use my body and voice expressively. _____ 
 
8. My thoughts become confused and jumbled when I speak before an audience. _____ 
 
9. I have no fear of facing an audience. _____ 
 
10. Although I am nervous just before getting up I soon forget my fears and enjoy the experience. 
____ 
 
11. I face the prospect of making a speech with complete confidence. _____ 
 
12. I feel that I am in complete possession of myself while speaking. _____ 
 
13. I prefer to have notes on the platform in case I forget my speech. _____ 
 
14. I like to observe the reactions of my audience to my speech. _____ 
 
15. Although I talk fluently with friends I am at a loss for words on the platform. ____ 
 
16. I feel relaxed and comfortable while speaking. _____ 
 
17. Although I do not enjoy speaking in public I don’t particularly dread it. _____ 
 
18. I always avoid speaking in public if possible. ____ 
  
19. The faces of my audience are blurred when I look at them. ____ 
  
20. I enjoy preparing a talk. ______ 
 
21. My mind is clear when I face an audience. _____ 
 
22. I am fairly fluent.  ______ 
 
23. I perspire and tremble just before getting up to speak. _____ 
 
24. My posture feels strained and unnatural. ______ 
 
25. I am fearful and tense all the while I am speaking before a group of people. ______ 
 
26. I find the prospect of speaking mildly unpleasant. ______ 
 
27. It is difficult for me to calmly search my mind for the right words to express my thoughts. _____ 
 
28. I am terrified at the thought of speaking before a group of people. _______ 
 
29. I have a feeling of alertness in facing an audience. _______ 
 
30. I feel disgusted with myself after trying to address a group of people. _______ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendix B.  
Fear of Negative Evaluation – Brief Form 
 Read each of the following statements and then use the scale below to indicate the degree to which 
each statement applies to you, use the blank to enter the number that corresponds to your answer for 
each question. 
 1                              2                              3                              4                              5                      
    Not at All            Slightly         Moderately                  Very                   Extremely          
 
 
1. I worry about what other people will think of me even when I know that it doesn’t make 
any difference. __________ 
 
2. I am unconcerned even if I know people are forming an unfavorable opinion of me. ________ 
 
3. I am frequently afraid of other people noticing my short comings. _______ 
 
4. I rarely worry about what kind of impression I am making on someone. _______ 
 
5. I am afraid that others will not approve of me. ________ 
 
6. I am afraid that people will find fault in me. ________ 
 
7. Other people’s opinions of me do not bother me. _______ 
 
8. When I am talking to someone, I worry about what they may be thinking about me. ______ 
 
9. I am usually worried about what kind of impression I make. _______ 
 
10. If I know someone is judging me, it has little effect on me. ______ 
 
11. Sometime I think I am too concerned with what other people think of me. _______ 
 
12. I often worry that I will say or do wrong things. ________ 
 
 
 
 
 
 
 
 
 
 
 Appendix C.  
Liebowitz Social Anxiety Scale (LSAS-SR) 
 
Fill out the following questionnaire with the most suitable answer listed. Base your answers on your 
experience in the past week and, if you have completed the scale previously, be as consistent as possible 
in your perception of the situations described. Be sure to answer all items. 
 
Fear or Anxiety Avoidance 
►  0 = None ►  0 = Never  (0%) 
►  1 = Mild ►  1 = Occasionally  (1% - 33% of the time) 
►  2 = Moderate ►  2 = Often  (33% - 67% of the time) 
►  3 = Severe ►  3 = Usually  (67% - 100% of the time) 
  
 
       Fear or Anxiety       Avoidance 
 
1. Telephoning in public–speaking on the telephone        ______                   ______    
               in a public place 
 
2. Participating in small groups–having a discussion         ______         ______ 
               with a few others  
 
3. Eating in public places–do you tremble or feel        ______         ______       
awkward handling food 
 
4. Drinking with others in public places–refers to         ______         ______  
any beverage including alcohol 
 
5. Talking to people of authority–for example,          ______          ______ 
 a boss or a teacher         
 
6. Acting, performing, or giving a talk in front of an          ______          ______  
audience–refers to a large audience 
 
7. Going to a party–an average party to which            ______         ______ 
you may be invited; assume you know some  
but not all people at the party 
 
8. Working while being observed–any type of work          ______         ______ 
you might do including school work or housework 
 
9. Writing while being observed–for example,          ______         ______ 
signing a check in a bank 
 
10. Calling someone you don’t know very well          ______         ______ 
  
  
Fear or Anxiety       Avoidance 
 
11. Talking with people you don’t know very well        ______        ______ 
     
12.       Meeting strangers–assume others are of average        ______       ______ 
      importance to you 
13. Urinating in a public bathroom–assume that others        ______               ______ 
                     are sometime present, as might normally be expected 
 
14.  Entering a room when others are already seated–       ______       ______ 
                     refers to a small group, and nobody has to move  
       seats for you 
 
15. Being the center of attention–telling a story to a       ______      ______ 
             group of people 
 
16. Speaking up at a meeting–speaking from your       ______      ______  
            seat in a small meeting or standing up in place in a  
            large meeting 
 
17. Taking a written test          ______      _______ 
 
18. Expressing appropriate disagreement or disapproval      ______     _______ 
            to people you don’t know very well 
 
19. Looking at people you don’t know very well in the       ______      ______   
           eyes–refers to appropriate eye contact 
 
20. Giving a report to a group–refers to an oral report       ______     ______   
in front of a small group 
 
21. Trying to pick up someone–refers to a single person        ______                ______  
attempting to initiate a relationship with a stranger 
 
22.  Returning goods to a store where returns are       ______        ______         
normally accepted    
         
23.  Giving an average party           ______        ______ 
 
24.         Resisting a high pressure sales person–avoidance       ______        ______ 
             refers to listening to the salesperson for too long 
 
 
 
 
 
  
Appendix D. 
Long- Term Follow-up Questionnaire 
 
Thank you again for your participation. Information about your experiences is critical to our research 
and treatment program. Please take a few moments to help us evaluate the effectiveness of our 
treatment by filling out all of the questions. When answering the questions please think about what has 
happened since completing treatment in _________________________.  
 
1. Since completing treatment, how often have you spoken in public: 
________  not at all 
________  not much, I still avoid 
________  not much, no opportunity 
________  whenever I needed to 
 
2. Approximately how many times have you spoken in public since completing treatment: __________ 
                                                                                                                                                             
3. What types of public speaking activities have you done (e.g. spoken up at meetings, class, church, size 
of audience, etc)?    
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
 
4. How comfortable were you the most recent time you spoke in public? 
 ____ 1. Very comfortable 
 ____ 2. Quite comfortable 
 ____ 3. Minimally comfortable 
 ____ 4. Neutral 
 ____ 5. Minimally uncomfortable 
 ____ 6. Quite uncomfortable 
 ____ 7. Very uncomfortable 
 
5. Since completing treatment, have you used alcohol or drugs (e.g., beta blockers) to help you during 
public speaking activities? If so, what have you used?  
__________________________________________________________________________________ 
______Never 
______Rarely 
______Sometimes 
______About half the time 
______Almost all the time 
______Every time 
 
6. What is the most important thing you learned from treatment (use back if necessary)? 
__________________________________________________________________________________
__________________________________________________________________________________ 
 
  
7. Looking back, please tell us what you would change about the program (use back if necessary)?  
__________________________________________________________________________________
__________________________________________________________________________________ 
 
8. Which homework assignments do you feel were most/least helpful? Is there anything you would 
change about the homework assignments (use back if necessary)? 
__________________________________________________________________________________
__________________________________________________________________________________ 
 
9. We want to know how much you have used what you learned during the research study and whether 
it has been helpful. Please use the scale below to rate each item according to the frequency of use 
and the degree to which it has been helpful (use “na” for not applicable).  
 
 
 
           
 1                  2                   3                   4                 5                   6                   7                   8               9 
     Haven’t Used                          Sometimes Use              Often Use 
    Not Helpful           Somewhat Helpful        Very Helpful 
 
 
 
Frequency Helpfulness 
 
 ________ _________ Taking calming breaths 
   
________ _________ Learning about public speaking anxiety (i.e., avoidance makes it worse) 
     
________ _________ Setting realistic expectations for myself 
 
________ _________ Refraining from thinking only about negative aspects of my    
               performance afterwards. 
 
________ _________ Focusing my attention off of myself while I am speaking. 
 
________ _________ Identifying specific goals for speaking situations. 
 
________ _________ Getting a more realistic image of how I come across to others. 
 
________ _________ Refraining from using safety behaviors--things that give me an artificial  
sense of comfort or safety (e.g., like holding on to an object, so others 
can’t see my hands shaking) 
 
________ _________ Practice watching myself (e.g., mirror, on videotape, on webcam) 
 
________ _________ Continuing to do public speaking (even when it doesn’t feel  
               comfortable) 
  
 
Frequency Helpfulness 
 
________ _________ Continuing to face my fears. 
 
________ _________ Trying to put it out of my mind/distract yourself 
 
________ _________ Support from therapist 
 
________ _________ Other: (please describe)   
__________________________________________________ 
  
 
Talking back to negative thoughts (please rate the frequency/helpfulness of each of the statements 
below) 
    
 
Frequency Helpfulness 
 
________ _________ “The probability that I will perform poorly is lower than I think.” 
       
________ _________ “The consequence of a poor performance is not as bad as I think.” 
 
________ _________ “I have more control over my anxiety than I think.” 
       
________ _________ “My anxiety doesn’t show as much as I think.” 
 
________ _________ “No one expects me to perform perfectly.” 
 
________ _________ “I tend to focus on the negative, it is important for me to pay attention  
to positive cues too.” 
 
10. Have you had any other treatment (therapy) for public speaking anxiety since completing this 
treatment?   Yes  ______       No  ______ 
 
11. If so, what kind of treatment (therapy) and how long did it last?   
 
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________ 
 
12. Have you taken any medication specifically for public speaking anxiety since completing this 
treatment?   
      Yes  ______       No  ______ 
 
 
 
  
13. If you’ve had other treatment in what ways was it similar or different from the treatment you 
received in the study? 
__________________________________________________________________________________
__________________________________________________________________________________ 
 
14. What was most/least helpful about the additional treatment that you received? 
__________________________________________________________________________________
__________________________________________________________________________________ 
 
15. Since completing treatment have you had a relapse in your fear?      Yes  _____         No  ______ 
       Please describe:  
__________________________________________________________________________________
__________________________________________________________________________________ 
 
16. Do you think you require additional treatment or booster sessions?     Yes  _____       No  ______ 
 
17. If you think you need additional treatment please tell us what you need help with: 
__________________________________________________________________________________
__________________________________________________________________________________ 
 
 
 
Please indicate whether or not you would be interested in being contacted for future research 
opportunities.    _______Yes   _______ No  
 
 
 
 
Please continue to next page 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Please help us understand the course of your public speaking anxiety and sense of improvement since 
completing treatment by using the following scales to rate how you. We have written in relevant dates 
to help you remember. Please include a rating for each time period.   
 
Compared to how I felt before beginning this study, ________ after completing treatment I felt:   
(1)   Very much improved 
(2)   Much improved 
(3)   Minimally improved 
(4)   Unchanged 
(5)   Minimally worse 
(6)   Much worse 
(7)   Very much worse 
 
 2 Years After 
Study 
3 Years After  
Study 
4 Years After  
Study 
5 Years After 
Study 
 Date: 
___________ 
Date: 
____________ 
Date: 
_____________ 
Date: 
___________ 
     
Very Much 
Improved 
1 1 1 1 
 
Much 
Improved 
 
2 
 
2 
 
2 
 
2 
 
Minimally 
Improved 
 
3 
 
3 
 
3 
 
3 
 
Unchanged 
 
4 
 
4 
 
4 
 
4 
 
 
Minimally 
Worse 
 
5 
 
5 
 
5 
 
5 
 
Much  
Worse 
 
6 
 
6 
 
6 
 
6 
 
 
Very Much 
Worse 
 
7 
 
7 
 
7 
 
7 
 
 
Please note any life events/ positive or negative experiences (i.e., additional treatment, job change, 
different types of public speaking opportunities, negative/positive public speaking experiences) that 
may have impacted your public speaking fears, since completing treatment. Also, please try to specify 
the approximate time when these events/ experiences occurred (i.e., 2, 3, 4, or 5 years after treatment).  
_____________________________________________________________________________________
____________________________________________________________________________________ 
  Appendix E. 
LTF Medication Interview 
 
• Have you taken any medication specifically for public speaking anxiety since completing this 
treatment?  Yes  ______       No  ______ 
 
• Please record information regarding any medications that participants were taking during the 
study as well as any that they have taken since completing the study. Please include the 
following: 
o name of the medication  
o what the medication was for (i.e. public speaking anxiety, other psychological issues, 
medical issues) 
o the dosage 
o frequency (i.e. every day or only as needed) 
o duration (i.e how long medication was taken—record estimates if the participant does 
not remember exact dates.  
 
• Also, please note whether medications used during the study have/have not been discontinued 
during the follow-up period. If discontinued please record date. Also, please make of note of 
any dosage changes.   
 
 
Name? What for? 
 
Dose? How Often? Start 
Date? 
Stop 
Date? 
      
      
      
      
      
      
 
 
 
 Appendix F. 
Long-term Follow-up BAT – Participant Ratings  
 
 
 
 
 
 
 
 
Please use the following scale to rate your level of anxiety during each of the tasks below: 
 
      0      1      2      3      4      5      6      7      8      9      10                            
not at all              moderately                                                       extremely             
anxious                              anxious                                                               anxious 
 
 
_________    Waiting to get started 
_________    Listening to instructions 
_________    Preparing a talk 
_________    Being in front of the audience 
_________    Giving a talk 
_________    Post talk 
            ** copy from participant notecard 
 
 
Using the scale below please rate your performance (circle the number that corresponds with your 
answer). 
 
How good was the talk? 
 
0      1      2      3      4      5      6      7      8      9      10 
 not at all                                                                                       very good 
 
 
 
Compared to your pre-treatment speech, how would you rate today’s speech?   
  
0      1      2      3      4      5      6      7      8      9      10 
    much worse               same                       much  better 
 
 
 
 
 
 
 
Speaker ID   ________________                                Date   ________________________           
Card #  _____________________                Length   ______________________ 
Anxiety Ratings During Speech: 
 2 min _________ 
 4 min _________ 
 6 min _________ 
 8 min _________ 
             10 min _________ 
 Appendix G. 
 
Long-term Follow-up BAT – Audience Ratings 
 
 
 
 
 
 
 
 
 
Rater: Please answer the following demographic questions about yourself. 
 
How old are you?  _____________       
 
With what racial group do you most identify?  ____________ 
 
What is the gender you most identify with?  (Please circle response) Female     Male     Neither 
 
 
Please use the following scale to rate the participant’s performance and anxiety: 
 
 
0      1      2      3      4      5      6      7      8      9      10 
       not at all                                                                                     extremely 
                                                                                                  
 
 
_________    How good was the talk? 
 
_________    How anxious was the speaker? 
 
 
Comments for the speaker? 
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
____________________________________________________________________________________ 
 
 
        
Rater  ID   ________________                                Date   ________________________           
Speaker ID  _______________               Length   ______________________ 
